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Cancers are often associated with the mis-regulation of oncogenes and tumour 
suppressor genes. This thesis described the molecular cloning and characterization of 
OKL38, a candidate tumour suppressor gene. OKL38 is a novel pregnancy-induced 
growth inhibitor previously identified and isolated in our laboratory. The 18 kb OKL38 
gene residing in chromosome 16q23.3 contained 8 exons and 7 introns with exon size 
ranging from 92 to 1270 bp, was cloned and sequenced.  Four novel variants of OKL38 
were identified of which 3 were cloned and characterized. OKL38 was ubiquitously 
expressed in all tissues, with abundant transcripts detected in ovary, kidney, liver and 
testis. 
Concurrently, the rat OKL38 gene was cloned and characterized in order to 
establish a rat model to further unveil the functions and regulations of OKL38. Three 
novel rat OKL38 variants were identified, cloned and characterized. The tissues 
expression profiles of the rat OKL38 variants and the genomic structure of rat OKL38 
were deciphered. Using this rat model, the regulatory effects of pregnancy and hCG 
treatment on OKL38 expression in both the rat mammary gland and ovary was 
determined and the results suggested that OKL38 may have a protective role against 
carcinogenesis. 
Low level of OKL38 transcripts was detected in several breast cancer cell lines. In 
this study, loss or down-regulation of OKL38 mRNA was observed in 70% (14 of 20) of 
the kidney tumours using the cancer-profiling array (CPA) of paired normal/tumour 
cDNA. Western blot analysis revealed that OKL38 protein was undetectable in 78% (7 of 
 vii
9 pairs) of kidney tumour tissues and immunohistological analysis showed that 64% (14 
of 22) of kidney tumours either lost or under expressed OKL38 protein as compared to 
the adjacent normal tissue. The OKL38 protein was also lost or reduced in 64.2% (18 of 
28) of the HCC as compared to adjacent benign tissues and in all liver cancer cell lines 
examined. Immunohistochemical analysis demonstrated that OKL38 protein was 
undetected in 41.3% (38 of 92) of HCC, while 39.1% (36 of 92) showed weak staining. 
The lost or reduced expression of OKL38 correlated with high tumour stages (p=0.0042) as 
determined by non-parametric trend analysis. Our findings suggest that OKL38 plays an 
important role in tumour progression and indicate the potential use of OKL38 as biomarker 
for kidney and liver cancer.  
Beside its growth inhibitory role in MCF7 cells, the biochemical functions of 
OKL38 are unknown. However, over-expression of HuOKL38-eGFP recombinant 
protein in A498 and Chang liver cells lead to protein aggregation and cell death. The 
same phenomenon was observed when the RtOKL38-eGFP recombinant protein is over-
expressed in BRL cells suggesting that the OKL38 protein may play an important role in 
regulating cell death. Importantly, deletion studies revealed that the 5 untranslated 
region of OKL38 spliced variants played a critical role in regulating translation of 
OKL38 mRNA. Our data suggest that the loss of this protein may lead to the 
development and/or progression of cancers. A better understanding of the function of 
OKL38 in normal and tumour tissue may lead to the development of new preventive and 
therapeutic modalities for cancers of the kidney, liver, ovary and breast.   
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CHAPTER 1: LITERATURE REVIEW 
1.1 Functional Domains of Pyridine nucleotide-disulphide 
oxidoreductase and TrkA 
Proteins are modular in nature and its putative functions could be predicted via 
dissecting the domains. Some proteins that are essential for cell survival may have been 
functionally conserved throughout evolution, while others may have diversified to fulfil 
the needs of the complexity of organisms. Two of the evolutionary conserved domains, 
the pyridine nucleotide-disulphide oxidoreductase (Pyr_redox) and TrkA domain are 
being described.   
1.1.1 Proteins containing Pyridine nucleotide-disulphide 
oxidoreductase domain are bifunctional 
The Pyr_redox family of proteins consists of both class I and class II 
oxidoreductase, and also NADH oxidases and peroxidases. This family of proteins 
includes the well-characterized glutathione reductase and thioredoxin reductase proteins, 
which carry this domain in addition to a pyridine dimerization domain (Williams, 1995). 
It has been shown that the Thioredoxin (Trx) and Glutathione (GSH) system are involved 
in a variety of redox-dependent processes such as DNA synthesis, antioxidant defense 
and regulation of cellular redox state (Holmgren et al., 1998; Halliwell, 1999; Sies, 
1999). In addition, the Trx and GSH systems regulate the activities of various 
transcription factors, kinases and phosphatases, and they are implicated in the redox 
control of cell growth and death, transcription, cell signalling, and other processes (Rhee, 
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1999; Finkel, 2000). In the recent years, several proteins containing the oxidoreductase 
domain have been cloned and characterized. These genes include the apoptosis-inducing 
factor (AIF), p53-responsive gene 3 (PRG3)/ AIF-homologous mitochondrion-associated 
inducer of death (AMID) and the AIF-like (AIFL) gene (Daugas et al., 2000; Wu et al., 
2002; Ohiro et al., 2002; Xie et al., 2005), of which the AIF has been extensively studied.  
AIF is ubiquitously expressed in all tissues and cancer cell lines examined 
indicating that it could be an essential gene for important functions in the cell (Daugas et 
al., 2000). AIF is a phylogenetically old flavoprotein, which is confined to the 
mitochondrial intermembrane space in healthy cells (Cande et al., 2002). Upon lethal 
signaling, AIF would translocate from the mitochondria to the nucleus and induces 
apoptosis (Susin et al., 1999b; Joza et al., 2001; Ravagnan et al., 2001; Lipton and Bossy-
Wetzel, 2002; Yu et al., 2002; Hansen and Nagley, 2003; Cregan et al., 2004; Cande et 
al., 2004;). Over-expression of AIF can cause apoptosis independent of caspases (Susin et 
al., 1999a; Susin et al., 1999b), although one recent study demonstrated that AIF over-
expression was insufficient to induce apoptosis (Wu et al., 2002). In addition, AIF 
functions as a free radical scavenger (Klein et al., 2002) and plays a role in normal 
mitochondrial oxidative phosphorylation (Vahsen et al., 2004). A recent study 
demonstrated that AIF could suppress chemical stress-induced apoptosis involving 
reactive oxygen species (ROS) (Urbano et al., 2005). The precursor of mammalian AIF 
protein contains an N-terminal mitochondrial localization sequence (MLS, residues 1-
100) and a large C-terminal portion (121-610) that share similarity with bacterial 
oxidoreductase (Susin et al., 1999b). The human mature AIF has very similar crystal 
structure to oxidoreductase (Ye et al., 2002) and displays NAD(P)H oxidase as well as 
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monodehydroascobate reductase activities (Miramar et al., 2001). The NADH oxidase 
activity of AIF is essential for maintaining the transformed state of colon cancer cells 
(Urbano et al., 2005). While studies have shown that the oxidoreductase function of AIF 
is not required for its apoptogenic function (Loeffler et al., 2001; Miramar et al., 2001). 
Similar to cytochrome c, AIF is a bifunctional protein with an electron acceptor/donor 
(oxidoreductase) function and a second apoptogenic function.  
Heat shock proteins (HSP) are associated with AIF and may regulate its functions. 
The mitochondrial matrix protein HSP60 (heat shock protein 60) has an overlapping 
expression pattern to that of the AIF, as well as an identical subcellular distribution in 
histological section of human tissues (Daugas et al., 2000). HSP70 is known to show 
inhibitory properties to the apoptotic function of AIF (Ravagnan et al., 2001), suggesting 
that the HSP family of proteins may regulate the function of AIF in vivo.  
Following the discovery of AIF, the homologs of this gene were identified 
namely, AMID/PRG3 (Wu et al., 2002; Ohiro et al., 2002; Wu et al., 2004) and AIFL 
(Xie et al., 2005). AIFL and AMID/PRG3, which are distantly related to AIF, have 
recently been described to exert a pro-apoptotic function. The AMID/PRG3 protein, like 
AIF, has significant homology with NADH oxidoreductase/flavoproteins from bacterial 
to mammalian species, but do not possess a recognizable MLS (Wu et al., 2002; Ohiro et 
al., 2002). Recent reports about the localization of AMID/PRG3 have been unclear (Wu 
et al., 2002; Ohiro et al., 2002). Wu et al. (2002) observed that AMID/PRG3 associate 
with the outer mitochondrial membrane and tissue distribution was undetectable in heart, 
brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, 
testis, ovary, small intestine, colon and peripheral blood leukocyte; while expression 
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could be detected easily in colon cancer cell lines DLD and HCT116 and weak 
expression in B lymphoma cell line RPMI8226. On the other hand, Ohiro et al. (2002) 
reported the localization of AMID/PRG3 in the non-mitochondrial cytoplasm with high 
level of expression in heart, moderate level in liver and skeletal muscle, and low level in 
the placenta, lung, kidney and pancreas (Ohiro et al., 2002). Both groups have 
collectively shown that AMID/PRG3 expression is inducible by p53 (Ohiro et al., 2002; 
Wu et al., 2004) and down-regulated in tumour (Wu et al., 2004). Similar to AIF, the 
over-expression of AMID induces apoptosis in a caspase independent manner (Wu et al., 
2002).  
The recently characterized human AIFL, a homolog of AIF, contains a 
characteristic Rieske and a Pyr_redox domain (Xie et al., 2005). AIFL bears similar 
expression profiles to AIF and is predominantly localized to the mitochondria inner 
membrane. In addition, over-expression of AIFL induced apoptosis through the segment 
1-190 containing the Rieske domain (Xie et al., 2005). AIFL is distinct from AIF in that 
induction of apoptosis is caspase-dependent (Xie et al., 2005). In all cases mentioned, the 
oxidoreductase domain in the AIF, AMID/PRG3 and AIFL does not seem to play a part 
in their apoptogenic function (Miramar et al., 2001; Loeffler et al., 2001; Wu et al., 2002; 
Ohiro et al., 2002; Xie et al., 2005).  
A candidate tumour-suppressor gene, WW domain-containing oxidoreductase 
(WWOX/WOX1/FOR) has been reported to possess aberrant behaviours in breast, ovary, 
esophagus, lung, and liver cancers (Bednarek et al., 2000; Paige et al., 2001; Yakicier et 
al., 2001; Driouch et al., 2002; Kuroki et al., 2002; Yendamuri et al., 2003; Park et al., 
2004). In addition to the oxidoreductase domain, the WWOX also contain two N-terminal 
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WW domains and a nuclear localization sequence (NLS) (Chang, 2002). Over-expression 
of the full-length or the WW domain of WWOX sensitizes the TNF-resistant Cos7 cells 
to TNF killing (Chang et al., 2001). All these examples seem to suggest that genes 
containing the oxidoreductase domain may be bifunctional; (i) involved in regulating 
cellular redox and (ii) regulating cell death. 
1.1.2 Evolutionary conservation of potassium channels containing 
TrkA domain 
Potassium (K+) channels are ubiquitous in the animal and plant kingdoms and in 
yeast and bacteria exhibiting extraordinary heterogeneity among these organisms while 
preserving several salient features (Hille, 1992). These potassium channels contribute to 
the control of potassium flow, cell volume, release of hormones and transmitters, resting 
potential, and excitability of neurons and muscles (Jan and Jan, 1997). Two K+ uptake 
systems exist in the bacteria, Escherichia coli; consisting of the inducible Kdp system 
and the Trk system, which is constitutively expressed (Rhoads et al., 1976). The Trk 
consists of a transmembrane protein named TrkH or TrkG, which is the actual K+-
translocating subunit, and the cytoplasmic membrane surface protein TrkA, which is a 
NAD+ binding protein (Bossemeyer et al., 1989; Schlosser et al., 1993). The structure of 
TrkA protein consists of two similar halves: (i) N-terminal part of each TrkA half 
(residues 1-130 and 234-255, respectively) is similar to the complete NAD+-binding 
domain of NAD+-dependent dehydrogenases; (ii) C-terminal part of each TrkA half 
(residues 131-233 and 357-458, respectively) aligns with the first 100 residues of the 
catalytic domain of glyceraldehydes-3-phosphate dehydrogenase (Schlosser et al., 1993). 
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Jan and Jan (1997) have highlighted the similarity between the Trk system in 
bacteria and the voltage-gated potassium channels in mammals. The mammalian voltage-
gated potassium channels consist of the transmembrane -subunits and the cytoplasmic 
associating -subunits. The -subunits is postulated to play a role in regulating the 
channel activity according to the level of energy and/or reducing power of the cell (Jan 
and Jan, 1997). The -subunits of the voltage-dependent K+ channels seems to be the 
functional mammalian homologs of the bacteria TrkA protein. The -subunits sequences 
show significant similarity to members of the NAD(P)H-dependent oxidoreductase 
superfamily (McCormack and McCormack, 1994), containing a potential NAD(P)H-
binding motif but lacks membrane-spanning sequences (McCormack and McCormack, 
1994; Scott et al., 1994; Rettig et al., 1994).                
1.2 Translation control by 5 Untranslated region 
Regulation of gene expression can be achieved at various levels, such as 
transcription, post-transcriptional processing, mRNA stability, translation, post-
translational modifications and protein degradation. At the translation level, regulation of 
protein expression is crucial, especially in the absence of transcription as seen in early 
developmental stages or during cellular stress where general translational mechanism is 
inhibited. The presence of cis-elements in the 5 and 3-untranslated regions (UTR) play 
an important role in determining the translational efficiency and the initiation site for 
protein synthesis. Some of these elements include upstream ORF (uORF), upstream AUG 
(uAUG), GC-content, iron-response element (IRE), internal ribosomal entry segment 
(IRES) among others. Together with the ribosomal scanning process, complex 
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translational regulatory mechanisms are achieved to ensure proper regulation of proteins 
involved in cellular functions.    
1.2.1 Kozak sequence and translation initiation mechanisms 
In higher eukaryotes, the ideal Kozak consensus sequence is CCRCCAUGG, with 
the most conserved nucleotides being R (A or G) at 3 and G at +4 (the A of the AUG 
codon is designated as +1) (Kozak, 1981; Kozak, 1984; Kozak, 1986). These Kozak 
sequences would generally be present at the AUG of the main ORF (95-97% of the 
cases), while only 43-63% of uAUG contain these consensus sequences (Meijer and 
Thomas, 2002). In addition, the presence of a hairpin, approximately 14nt downstream of 
the AUG is necessary for effective initiation of translation (Kozak, 1990). 
The uAUGs can induce the formation of a translation-competent ribosome that 
may translate and (i) terminate and re-initiate, (ii) terminate and leave the mRNA, 
resulting in down-regulation of translation of the main ORF, or (iii) synthesize an N-
terminally extended protein (Meijer and Thomas, 2002). The leaky scanning model 
described that in the presence of uAUG, some of the ribosomes in the scanning initiation 
complex may skip the uAUG and initiate at the main ORF [start AUG (sAUG)] (Kozak, 
1978). In the presence of uORF, the re-initiation model being a very inefficient 
mechanism is proposed. In this case, the 40S ribosomal subunit remains connected to the 
mRNA after termination at the uORF and resumes scanning. Initiation can only take 
place at the next AUG provided that the 40S subunit is reloaded with eIF2-GTP-Met-
tRNAi (Miller and Hinnebusch, 1989). 
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1.2.2 Upstream ORF and AUG regulate translation of mRNAs 
In most cases, 5UTRs that enable efficient translation are short, have low GC 
content, are relative unstructured and do not contain uAUG codon (Kochetov et al., 
1998). The leader sequences of approximately 90% of vertebrate mRNAs examined to 
date are between 10 and 200 bases long, yet two thirds of the mRNAs known to encode 
proto-oncogenes or factors related to cell proliferation contains atypical 5 untranslated 
regions which are more than 200 bases long and/or contain more than one AUG codon 
(Kozak, 1987; Kozak, 1991). In general, the presence of uAUGs in the 5UTR would 
decrease the initiation efficiency on the sAUG preceding the main ORF (Morris and 
Geballe, 2000). A summary of the 5UTRs discussed in the following text and their 
mechanisms of uORF-mediated control were illustrated in figure 1.1. 
The uAUGs and uORFs have been demonstrated to play important roles in 
mediating translational control during cellular stress. One of the classical examples is the 
translation regulation of GCN4 transcription factor in the yeast, which is involved in 
amino acid synthesis (Hinnebusch, 1996). The 5UTR of the GCN4 contains 590 nt and 
four uORFs (Fig. 1.1). Under normal conditions, the ribosomal subunits are capable of 
re-initiation upon reaching uAUG4, translate the uORF4, terminate and leave the mRNA, 
without translating the GCN4 ORF. When general protein synthesis is inhibited, only half 
of the ribosomal complexes are in time for re-initiation and termination at uORF4; while 
the rest will only be reloaded with eIF2-GTP-Met-tRNAi for initiation after scanning the 
remaining 150 nt of the 5UTR, enabling the translation of the GCN4 ORF.  
The translation of activating transcription factor 4 (ATF4) in the mammal is also 
inducible by stress (Harding et al., 2000). The mouse ATF4 5UTR (272 nt) contains two 
  LITERATURE REVIEW 
________________________________________________________________________ 
 9
  LITERATURE REVIEW 
________________________________________________________________________ 
 10
uORFs, of which the second uORF overlaps with the ATF4 ORF (Fig. 1.1). Stress 
activates the mammalian eIF2 kinases PERK (PKR-like ER kinase) and GCN2, which 
repress translation of most mRNAs by phosphorylating eIF2 but selectively increase 
translation of ATF4. Mutation in either of the 2 uAUGs leads to drastic increase in 
translational efficiency suggesting that these uAUGs possess a general translation 
suppression function. 
Another regulatory function of uAUGs is to determine the initiation at different 
AUG codons, resulting in synthesis of proteins with N-terminal of different length. The 
CCAAT/enhancer binding protein (C/EBP) family of transcription factors, which are 
important for differentiation and cell proliferation. Both the C/EBP and C/EBP 
mRNAs contain an uORF in a reading frame different from the C/EBP reading frame 
(Fig. 1.1). Four (C/EBP) or three (C/EBP) potential translation initiation sites are 
present in the same reading frame, enabling the synthesis of several proteins with 
different N-terminal extension and an identical C-terminal DNA-binding domain (i.e. 
activating domain is missing from the shorter isoforms with truncated N-terminal). 
Therefore the isoforms ratio is crucial for the activity of this protein and is dependent on 
the presence of the out-of-frame uORF. The expression of the shorter isoforms is 
dependent on the re-initiation after the uORF translation (Calkhoven et al., 2000). The 
binding of CUG repeat binding protein 1 (CUGBP1) to the CUG repeats 5 to the uORF 
and the CCG repeats in the uORF of C/EBP stimulates the translation of truncated 
C/EBP isoforms, and therefore inhibiting C/EBP-dependent transcription of target gene 
(Timchenko et al., 1999). The translation of proto-oncogene fli-1 is regulated by two 
uORFs, which determine the synthesis of two protein isoforms (i.e. 48 kDa and 51 kDa). 
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Initiation at the 48 kDa isoform AUG is stimulated by enabling re-initiation after the 
translation of the uORF (Sarrazin et al., 2000).  Similar mechanism also regulates 
translation of the 2,3-cyclic nucleotide 3-phosphodiesterase (CNP2) mRNA (Fig. 1.1) 
(O'Neill et al., 1997). 
Stalling of ribosomes at uORFs is another important mechanisms employed to 
regulate the translation efficiency of the main ORF of mRNA. Interestingly, the peptide 
sequences encoded by the uORFs, not the nucleotide sequences, are involved in the 
repression of translation of the human cytomegalovirus early glycoprotein (gpUL4) (Cao 
and Geballe, 1995), S-Adenosylmethionine decarboxylase (AdoMetDC) (Ruan et al., 
1996), arg-2 (Fang et al., 2000), and Xenopus lavis connexin-41 (Meijer et al., 2000) 
mRNA (Fig. 1.1). Beside uORFs, stalling mechanism can be due to the presence of 
secondary structure (Ruegsegger et al., 2001) or adenine-rich element in the 5UTR as in 
the case of PABP1 mRNA (Bag, 2001). 
uORFs in the long 5UTR of mouse retinoic acid receptor 2 (RAR2) have been 
shown to be involve in the regulation of translation efficiency and localization-dependent 
translation (Zimmer et al., 1994; Reynolds et al., 1996). The translation of two uORFs in 
the yeast transcription factors YAP2 5UTR stimulates the decay of the YAP2 mRNA 
(termination-dependent decay) (Vilela et al., 1999). These examples illustrate the 
versatility of uORFs or uAUGs in regulating translation of mRNA.       
1.2.3 Internal ribosome entry segment and their cognate transacting factors 
orchestrate the regulation of 5UTRs translation 
Two distinct mechanisms, cap-dependent scanning and internal ribosome entry 
are involved in the translation initiation in eukaryotic cells. Internal translation initiation 
  LITERATURE REVIEW 
________________________________________________________________________ 
 12
requires the formation of a complex RNA structure element termed internal ribosome 
entry segment (IRES), which is a complex RNA scaffold containing multiple sites for 
interaction with components of the translational apparatus such as eIF4G and eIF4E 
(Kolupaeva et al., 1998; Lopez and Martinez-Salas, 2000; Martinez-Salas et al., 2001). 
IRES are usually located in the 5UTR and may interact with trans-acting factors to 
recruit ribosome to initiate internal translation. It is estimated that about 10% of the genes 
may contain IRES and usually these genes are involved in control of cell growth and cell 
death (Stoneley and Willis, 2004). The IRES identified to date are generally GC-rich 
suggesting complex secondary structure. However, no common structure features have 
been found between IRES from different genes or closely related ones ( Le Quesne et al., 
2001; Stoneley and Willis, 2004; Jopling et al., 2004). It has been proposed that IRES 
functions as multiple structures modules and may also be involved in cap-dependent 
scanning mechanism (Stoneley et al., 2000; Le Quesne et al., 2001). RNA-RNA 
interactions between the 5 and 3 end of the IRES (Yaman et al., 2003) and presence of 
pseudoknot can inhibit its function (Le Quesne et al., 2001; Yaman et al., 2003). Primary 
sequence elements that are implicated in internal initiation have been identified in the 
IRESs of Gtx, Rbm3 and fgf2 (Chappell et al., 2000a; Bonnal et al., 2003; Chappell and 
Mauro, 2003). The function of these elements in the context of IRES is still unclear, but 
may be involved in ribosome recruitment (Stoneley and Willis, 2004).    
Factors that interact with IRESs known as internal initiation trans-acting factors 
(ITAFs) have been identified in recent years (Holcik and Korneluk, 2000; Mitchell et al., 
2001; Evans et al., 2003; Holcik et al., 2003; Pickering et al., 2003). ITAFs are generally 
located in the nucleus and shuttling between the nucleus and cytoplasm may constitute to 
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its function with IRES. Two of the ITAFs, upstream of N-ras (unr) and polypyrimidine 
tract-binding (PTB) protein, form a specific RNA-protein complex with Apaf-1 IRES and 
collectively stimulate Apaf-1 internal initiation (Mitchell et al., 2001). A similar 
mechanism has also been documented in the Bag-1 IRES. The RNA chaperone activities 
of PTB and poly-(rC)-binding protein 1 (PCBP1) unwind a specific region of the Bag-1 
IRES structure, thus stimulating its function (Pickering et al., 2003). ITAFs such as PTB 
can serve as a repressor of Bip internal initiation (Kim et al., 2000), suggesting that 
ITAFs, together with the IRESs could have either positive or negative regulatory effect 
on internal initiation (Stoneley and Willis, 2004). Others examples of ITAFs have been 
extensively described by Stoneley and Willis (2004). 
Despite extensive research on IRESs and ITAFs, the molecular mechanism of 
IRES is still unclear. Yaman et al (2003) have proposed that the activity of cat-1 IRES is 
regulated by two sequential events. This involves an initial translation of a small uORF 
within the 5UTR that cause structure remodeling of the IRES, leading to the attainment 
of an active IRES conformation; followed by the induction of cat-1 IRES activity, which 
is dependent on the phosphorylation of eIF2. However, it is clear that IRES is 
implicated in the regulation of gene expression in diverse physiological states (i.e. amino 
acid starvation, cell-cycle arrest, programmed cell death, hypoxia, etc) enabling cells to 
respond to these conditions against the background of a general reduction in protein 
synthesis.  
1.2.4 Cancer derived from mis-regulation of translation by 5UTR 
The translation initiation factor, eIF4E is associated with tumourigenesis as many 
mRNAs associated with growth contains highly structured 5UTRs. Over-expression of 
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eIF4E relieves the translational repression imposed on structured 5UTRs (Koromilas et 
al., 1992; Zimmer et al., 2000) and increased level is associated with a number of tumour 
types, including breast, head-and-neck, bladder, liver and colon cancer (Kevil et al., 
1995; Rousseau et al., 1996; Nathan et al., 1997; DeFatta et al., 1999; Zimmer et al., 
2000; Crew et al., 2000). The elevated level of eIF4E was suggested to increase the 
translation of oncogenes with highly structured 5UTRs, such as c-myc and ornithine 
decarboxylase (ODC), and mRNAs that encode proteins involved in angiogenesis, such 
as fibroblast growth factor 2 (FGF2) and vascular endothelial growth factor (VEGF) 
(Kevil et al., 1995; Rousseau et al., 1996; Nathan et al., 1997; DeFatta et al., 1999; 
Zimmer et al., 2000; Crew et al., 2000). 
De-regulation of translation of mRNAs containing translation-inhibitory 5UTRs 
often occurs by the production of alternate transcripts with shorter version of the 5UTR 
that is often translated efficiently. Genes regulated in this manner include members of the 
transforming growth factor beta (TGF-), BRCA1, and the murine double minute gene 2 
(mdm2). The TGF-1 expresses three transcripts, differing in their translational 
efficiencies due to the alternative length of their 5UTRs, all are GC-rich and involved in 
the inhibition of translation of this mRNA (Kim et al., 1992; Romeo et al., 1993; Allison 
et al., 1998). The TGF-3 mRNA has a long 1.1 kb 5UTR that is inhibitory to translation 
with de-regulated expression being associated with disease. Many human breast cancer 
cell lines expressed a novel TGF-3 transcript that possess a 5UTR which is 870 
nucleotides shorter than the longer version of 1.1 kb. This mRNA isoform with short 
5UTRs confer 7-fold higher translational efficiency, thus leading to cell transformation 
(Arrick et al., 1991; Arrick et al., 1994). 
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Over-expression of BRCA1 protein results in growth inhibition of tumours (Holt 
et al., 1996). BRCA1 mRNAs can be expressed from two promoters,  and , resulting in 
alternative exon 1a and 1b. Incidentally, the ORF begins in exon 2 resulting in mRNAs 
with different 5UTRs. BRCA1b transcripts were found to be expressed in breast cancer 
tissues but not in normal mammary glands, where the BRCA1a transcripts were 
predominantly expressed (Sobczak and Krzyzosiak, 2002). The BRCA1b mRNA was 
found to have a longer 5UTRs with comparably stable secondary structure and uAUG, 
which together contribute to a 10-fold reduction in translational efficiency compared to 
BRCA1a (Sobczak and Krzyzosiak, 2002). Thus, loss of BRCA1 protein in breast cancer 
is partially due to the preferential expression and translational suppression of BRCA1b 
mRNA.  
The Mdm2 gene encodes a nuclear phosphoprotein, which binds to p53 tumour-
suppressor gene for destruction by the ubiquitin-dependent proteasome pathway. Two 
constitutively expressed transcripts of mdm2 were derived from alternative promoters. 
The longer transcript is inhibitory to scanning by ribosome, while the other variant, 
which is inducible by p53 contains a short 5UTR (68 nt) that is translated more 
efficiently than the former (Landers et al., 1997). In Burkitts lymphoma cells with wild 
type p53, over-expression of Mdm2 is due to enhanced translation, through up-regulation 
of mdm2 transcripts with short 5UTR (Capoulade et al., 1998, 2001). 
IRESs may be present in the long 5UTRs and the mechanisms of IRES-regulated 
translation were described in Section 1.2.3. The ability of IRESs to function under 
condition of cell stress is particularly relevant for tumour progression. IRESs have been 
demonstrated to drive translation of angiogenic growth factors, such as FGF2 and VEGF 
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under hypoxic condition, when cap-dependent translation is compromised (Stein et al., 
1998; Akiri et al., 1998; Huez et al., 1998; Townsend et al., 2003). In addition, 
transcription of VEGF could be activated by the transcription factor hypoxia-inducible 
factor 1 (HIF-1), which contains IRES that function during hypoxia (Lang et al., 2002). 
These cooperative regulations of protein translation during hypoxic condition promote 
tumour growth. 
Aberrant translational regulation through an IRES-mediated mechanism has been 
identified in the human neoplasia multiple myeloma (MM). Significantly increased level 
of c-myc protein was found in MM cell lines and correlated to a single C to U transition 
in the c-myc 5UTR (Paulin et al., 1996). The same mutation was also identified in 42% 
of bone marrow samples collected from MM patients (Chappell et al., 2000b). This 
mutation enhances the interaction between the ITAF, hnRNPK, and IRES, resulting in 
increased activity of the c-myc IRES (Paulin et al., 1998; Evans et al., 2003). Thus 
leading to over-expression of c-myc protein resulted in expansion of a plasma cell type in 
the bone marrow and osteolysis. These examples strongly illustrated the importance of 
5UTRs functions in regulating translation of genes related to cancers and their 
expression is associated to the progression of the disease.                            
1.3 Hepatocellular Carcinoma 
The major risk factors and etiological agents responsible for development of 
hepatocellular carcinoma (HCC) in humans have been extensively identified and 
characterized. Among these include chronic infection with hepatitis B and C virus, 
exposure to aflatoxin B1, and cirrhosis of any etiology. Generally, the neoplastic 
transformation of hepatocytes is the result of the accumulation of genetic damage during 
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the repetitive cellular proliferation that occurs in the injured liver in response to paracrine 
growth factor and cytokine stimulation. These genetic alteration including chromosomal 
deletion, rearrangements, aneuploidy, gene amplifications, and mutations, as well as 
epigenetic alteration, resulting in activation of proto-oncogenes and inactivation of 
tumour-suppressor genes, leading to cells acquiring autonomous growth potential. The 
mechanisms of hepatocarcinogenesis and potential biomarkers for HCC are briefly 
discussed in the following sections. 
1.3.1 Epidemiology and Etiology of hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) accounts for more than 90% of all primary liver 
cancers. HCC represents approximately 40% of all cancers in South-East Asia, Japan and 
Africa (Akriviadis et al., 1998), with much lower incidence rates found in Europe and the 
Americas (Mathers et al., 2002). High incidence of HCC is found in China, where men 
exhibit an incidence rate of approximately 36 cases per 100,000 populations (Parkin et 
al., 1999; Mathers et al., 2002). Extremely high incidences of HCC of 113 cases per 
100,000 populations are observed among black males in Mozambique (Higginson, 1963). 
These observations strongly suggest that factors related to genetic background and/or 
environmental exposure contributes significantly to the incidence of this tumour among 
world population. 
Estimates from the year 2000 indicate that liver cancer remains the fifth most 
common malignancy in men and the eighth in women worldwide with number of new 
cases estimated to be 564,000 per year (Bosch et al., 2004). Men are more prone to 
develop liver cancer compared to women. In the United State, ratio of male to female 
incidence is approximately 2:1 (Jemal et al., 2003), and world-wide is approximately 
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2.6:1 (Parkin et al., 1999). However, in high incidence countries or world region, the 
male to female incidence ratio can be as high as 8:1 (Simonetti et al., 1991). This 
consistently higher incidence in men than women suggest that sex hormone and/or their 
receptors may play a significant role in the development of primary liver tumours. 
The etiology of human hepatocellular carcinoma is multi-factorial (Hassan et al., 
2002). Causative factors such as exposure to naturally occurring carcinogens, industrial 
chemicals, pharmacologic agents, and various pollutants, which may contribute to the 
development of HCC have been identified (Grisham, 1995; Grisham, 1997). Exposure to 
hepatotoxic drugs and chemicals such as the radioactive compound thorium dioxide (used 
in imaging of blood vessels) (Andersson et al., 1994), vinyl chloride monomer (Du and 
Wang, 1998), pesticides (Austin et al., 1987), anabolic steroids and oestrogen (Vainio 
and Wilbourn, 1993); and inorganic arsenic compounds (Chen et al., 1992) can lead to 
the development of liver cancer. 
Genetic liver diseases, mostly related to inborn errors of metabolism that result in 
the accumulation of metabolic products in hepatocytes, can lead to chronic hepatitis and 
cirrhosis, unfortunately, increases the risk of development of HCC (Hadchouel, 1994). 
These genetic conditions include hemochromotosis (Deugnier and Turlin, 2001), 
hereditary tyrosinemia (Russo and O'Regan, 1990), glycogen storage diseases (Bianchi, 
1993), Wilsons disease (Wilkinson et al., 1983) and 1-antitrypsin deficiency (Propst et 
al., 1994). 
Other factors such as hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infection and alcohol consumption contribute to the risk for development of HCC 
(International Agency for Research on Cancer, 1994c; Grisham, 1995; Grisham, 1997; 
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Schafer and Sorrell, 1999; Ince and Wands, 1999). Chronic infection with either HBV or 
HCV frequently results in chronic hepatitis and cirrhosis, which greatly increases the risk 
for the development of HCC in humans (100-fold to 200-fold) compared to uninfected 
individuals (International Agency for Research on Cancer, 1994b; Bailey and Brunt, 
2002). Chronic alcohol consumption is associated with an elevated risk for HCC (Ikeda et 
al., 1993; Nalpas et al., 1995; Noda et al., 1996). Chronic liver damage caused by alcohol 
contributes secondarily to liver tumour formation (Simonetti et al., 1992). Ethanol 
appears to potentiate the hepatocarcinogenicity of chronic HBV and HCV infection 
(Nalpas et al., 1995; Noda et al., 1996). Besides alcohol consumption, tobacco smoking is 
another important risk factor (Trichopoulos et al., 1980; Doll, 1996).   
Another major hepatocarcinogenic risk for human is the dietary consumption of 
aflatoxins B1 in food grains contaminated with Aspergillus flavus and related fungi 
(International Agency for Research on Cancer, 1994c; Schafer and Sorrell, 1999; Ince 
and Wands, 1999). Rice or other grains under improper storage conditions (Zimmerman 
H.J., 1978; Zimmerman H.J., 1999) lead to the growth of these aflatoxin producing 
moulds.  Aflatoxin B1 is a potent, direct acting carcinogen in humans and chronic 
exposure leads inevitably to development of HCC (International Agency for Research on 
Cancer, 1994a). In common among all of these etiologic factors is the risk for 
development of chronic hepatitis and cirrhosis. 
1.3.2 Molecular pathogenesis of hepatocellular carcinoma 
Continuous intensive studies have shed light on the molecular mechanisms of 
hepatocarcinogenesis (Grisha, 2002; Feitelson et al., 2002; Thorgeirsson and Grisham, 
2002; Coleman, 2003). Aneuploidy and abnormal chromosome numbers is a well-
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documented feature of HCC. Approximately 40% of HCC exhibit aneuploid DNA 
content and numerical chromosomal abnormalities (Mise et al., 1998; Kato et al., 1998). 
The presence of aneuploidy in dysplastic lesions suggests that genetic abnormalities may 
be a significant determinant of neoplastic transformation in the liver (Terris et al., 1997). 
The majority of cultured cells derived from HCC contained either a sub-tetraploid 
chromosome number (64-99 chromosomes) or near diploid (Bardi et al., 1998; Parada et 
al., 1998). The chromosomal regions most frequently involved in structural 
rearrangements include 1p11, 1p22, 1p32, 1p34, 1p36, 1q10, 1q12, 1q25, 6q13-q15, 
6q22-q25, 8q10, 16q24, and 17p11 (Grisha, 2002). In a particular study, chromosomes 
4q, 8p and 16q were affected in HBV-related HCC, while 11q was affected in HCV-
related HCC (Wong et al., 2000), indicating that specific genetic abnormalities can be 
attributed to specific etiological agents or mechanisms. 
Chromosomal gains have been described in HCC involving 1p, 4q, 5p, 6q, 8p, 9p, 
10q, 11q, 12q, 16q, 17p, and 19p, which may lead to gene amplification. Over-expression 
of proto-oncogenes may alter the intracellular signalling pathways leading to the 
unregulated cellular proliferation. These signalling pathways involve a number of 
positive mediators of cellular proliferation, including the protein products of the c-ras 
gene family, c-myc, c-fos and, various cyclins and cyclin-dependent kinases (Grisha, 
2002). This is supported by recent studies that demonstrate pronounced gain in copy 
numbers of c-myc for all 20 HCCs evaluated (Raidl et al., 2004). Other studies showed 
that the c-myc gene was amplified in 31% (50/163) of HCC examined (Lee et al., 1988; 
Fukuda et al., 1988; Peng et al., 1993; Abou-Elella et al., 1996; Kawate et al., 1999a) and 
  LITERATURE REVIEW 
________________________________________________________________________ 
 21
over-expression of c-myc mRNA in more than 90% of HCC (Su et al., 1985; Zhang et al., 
1990). 
The hepatitis viral proteins displayed a pronounced effect on the mechanism of 
hepatocarcinogenesis (Feitelson et al., 2002). The ability of the HBx oncogenic protein to 
induce c-myc and other proto-oncogenes has been demonstrated using microarray 
analysis (Wu et al., 2001). The levels of expression of c-myc protein are also increased in 
chronic hepatitis (Tiniakos et al., 1993), and cirrhosis (Tiniakos et al., 1989; Gan et al., 
1993).  In addition, over-expression of c-myc in HCC could also be due to an up-
regulation of the MAPK pathway (Grisha, 2002) and hypomethylation. The c-myc gene 
was found to be hypomethylated in 55% (15/27) of HCC and in significant percentage of 
cirrhotic liver adjacent to HCC (Nambu et al., 1987; Kaneko et al., 1985). These 
observations indicate that various mechanisms are involved in the genetic alteration of a 
single gene such as c-myc, leading to hepatocarcinogenesis. Interestingly, HCC due to 
HBV and HCV were also postulated to be an indirect result of enhanced hepatocytes 
turnover that occurs in an effort to replace infected cells that have been immunologically 
attacked (Block et al., 2003).  
Major growth factors implicated in hepatocellular carcinoma including TGF, 
insulin-like growth factor II (IGF-II), hepatocyte growth factors (HGF), and others were 
extensively described (Grisha, 2002; Feitelson et al., 2002; Coleman, 2003). More than 
20 HCC associated genes have been identified and they are found either down- or up-
regulated or mutated in HCC (Zeng et al., 2002). Using DNA microarrays, hundreds of 
genes involved in progression and metastasis of HCC have been identified (Ye et al., 
2003; Patil et al., 2005).  Over-expression of IGF-II and loss of IGF binding protein 3 
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(IGFBP3) were observed in a high proportion of HCC samples (Huynh et al., 2002). 
Over-production of pRb2/p130 in HepG2 cells led to growth suppression, cell cycle 
arrest at G0/G1, altered cell morphology, inhibition of in vitro colony formation and 
reduction in tumourigenicity in SCID mice (Huynh, 2004). These studies indicate that 
deregulation or functional loss of genes encoding growth factors leads to the development 
and progression of cancers. 
Microsatellite instability (MI) is a specific form of genomic instability that is 
characterized by mutational alteration of simple repetitive sequences, including both 
insertional and deletional mutagenesis, typically resulting in frameshift mutations. 
(Coleman and Tsongalis, 2002). Microsatellite alteration involving the TGFRII, 
M6P/IGFIIR, and BAX genes, which are critical for growth control and regulation of 
apoptosis, has been reported (Yakushiji et al., 1999). Microsatellite alteration involving at 
least two loci was detected in approximately 28% of the HCCs exhibiting MI (Horii et 
al., 1994; Salvucci et al., 1999), while others fail to identify MI in HCC (Kawate et al., 
1999b; Rashid et al., 1999). These studies suggest that MI may be mechanistically 
involved with the molecular pathogenesis of a subset of HCC (Coleman and Tsongalis, 
2002). 
The loss or progressive loss of tumour-suppressor genes and other negative 
mediators of cellular proliferation have been implicated in the molecular pathogenesis of 
HCC (Elmore and Harris, 1998; Grisha, 2002; Feitelson et al., 2002; Staib et al., 2003; 
Coleman, 2003). These tumour-suppressor genes and tumour-suppressor-like genes 
include p53, Rb1, p73, mdm2, APC, -catenin, E-cadherin, PTEN, BRCA1, FHIT, 
WWOX and others (Grisha, 2002). E-cadherin and WWOX are two of the potential 
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tumour-suppressor genes residing on chromosome 16q22 and 16q23, respectively 
(Niketeghad et al., 2001; Slagle et al., 1993; Park et al., 2004). The region 16q23 have 
been described as the second most active fragile site (FRA16D) in human the genome 
(Glover et al., 1984; Bednarek et al., 2000; Bednarek et al., 2001; Ludes-Meyers et al., 
2003) and both E-cadherin and WWOX reside on or close to FRA16D. LOH of 16q 
correlates with metastasis and loss of these genes via LOH have been described (Slagle et 
al., 1993; Niketeghad et al., 2001; Park et al., 2004). E-cadherin functions as a receptor in 
adherent junctions and is essential for the maintenance of tissue architecture. Mutations 
in E-cadherin causes its inability to bind -catenin, which leads to the accumulation of 
the latter in the cytoplasm and nucleus, resulting in constitutive Wnt activation and cell 
proliferation (Barth et al., 1997). In addition to LOH, hypermethylation of the E-cadherin 
promoter has been proposed as an alternative mechanism for Wnt activation in HCC 
(Kanai et al., 1997). The functions of WWOX in cancer have been described in Section 
1.1.1. In view of all the evidences, HCC is a very complex disease and genetic alteration 
leading to unregulated cellular proliferation resulting in hepatocarcinogenesis. 
1.3.3 Prognostic and diagnostic molecular markers for hepatocellular 
carcinoma 
The molecular mechanisms of hepatocarcinogenesis are complex, constantly 
evolving and heterogeneous, which explains the generally poor treatment outcomes for 
HCC. The majority of patients with HCC have inoperable disease with very poor 
prognosis (Okuda et al., 1985). Five-year survival rate is limited to 25 to 50% after 
surgery (Colombo, 1992; Lai et al., 1995; Takenaka et al., 1996). Long-term survival is 
uncommon because of the frequent recurrence, metastasis or the development of new 
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primary tumours (Lai, 1994; Huguet, 2000). Current adjuvant or palliative treatment 
modalities have not effectively prolonged survival in HCC (Chan et al., 2000). Therefore, 
the understanding of the disease and continuous search for a cure, including the 
development of diagnostic/prognostic molecular markers for HCC is crucial (Qin and 
Tang, 2002; Qin and Tang, 2004; Marrero and Lok, 2004). 
Conventionally, predictive factors for cancer relapse after surgical treatment 
consist of staging with the tumour node metastasis system (TNM) and grading by cellular 
differentiation; however, this cannot accurately predict the outcome of all HCC patients. 
The discovery and characterization of numerous HCC-associated genes serves as a 
platform for the identification of potential molecular biomarkers for HCC. Biomarkers 
are defined as indicators of cellular, biochemical, molecular, or genetic alterations by 
which normal or abnormal biological processes can be recognized (Srivastava and Gopal-
Srivastava, 2002). Biomarkers for molecular biological sub-staging may provide an 
opportunity to identify those patients with the most aggressive forms of the disease. 
Besides the traditional tumour-associated markers, such as alpha-fetoprotein, with new 
advances in molecular biological techniques and cancer biology, many biomarkers 
related to invasion, metastasis, recurrence, and survival have been explored (Korn, 2001).   
A large number of molecular factors have been shown to associate with the 
invasiveness of HCC, and provide prognostic significance. One aspect is to analyse the 
molecular markers for cellular malignancy, including DNA ploidy, cellular proliferation 
markers (PCNA, Ki-67, Mcm2, MIB1, MIA and CSE1L/CAS protein), nuclear 
morphology, cell cycle regulators (cyclin A, D and E, cdc2, p27, p73), oncogenes and 
their receptors (ras, c-myc, c-fos, HGF, c-met, and erb-B receptor family), tumour 
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suppressor (p53 gene and its related molecule mdm2), apoptosis related factors (Fas and 
FasL), as well as telomerase activity. The other aspect is to study the molecular factors 
involved in the process of HCC invasion and metastasis, which include adhesion 
molecules such as E-cadherin, catenins, CD44 variants, ICAM-1, laminin-5, osteopontin, 
proteinases responsible for the degradation of extracellular matrix (MMPs, uPA system), 
as well as angiogenesis regulators (VEGF, basic FGF, platelet-derived growth factor 
(PDGF), thrombospondin, angiogenin, pleiotroohin, endostatin, intratumour microvessel 
density). Another important aspect is to detect the transcripts of tumour associated 
antigen (such as AFP, MAGEs, and CK19), which have been proposed to be markers for 
metastatic recurrence of HCC (Qin and Tang, 2002; Qin and Tang,  2004). Factors that 
are involved in these biological processes and differentially expressed during the 
hepatocarcinogenesis may serve as potential diagnostic/ prognostic biomarkers for HCC. 
The tumour suppressor gene p53 plays a central role in cellular responses, 
including cell-cycle arrest and cell death in response to DNA damage. Loss of p53 
function can induce abnormal cell growth, increase cell survival, induce genetic 
instability, and drug resistance. Thus, p53 mutations are considered as strong marker 
candidates for predicting increased risk of local relapses, treatment failure, and overall 
disease-free survival in many kinds of human carcinomas, such as breast (Amornmarn et 
al., 2000; Blaszyk et al., 2000), colorectal (Diez et al., 2000; Kahlenberg et al., 2000), 
esophageal (Ireland et al., 2000), head and neck (Tamas et al., 2000), lung (Mitsudomi et 
al., 2000), and ovarian cancer (Shahin et al., 2000), as well as sarcoma (de Alava et al., 
2000). However, many other reports failed to show the independent prognostic value of 
p53 in cancer of the tongue (Kantola et al., 2000), breast (Ferrero et al., 2000), stomach 
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(Kaye et al., 2000), lung (Schiller et al., 2001), ovarian (Gadducci et al., 2000), bladder 
(Fleshner et al., 2000), colorectal (Gallego et al., 2000), and non-Hodgkinss lymphoma 
(Nieder et al., 2001). Similar controversial results were observed in the case of p53 
mutation and over-expression in HCC (Sugo et al., 1999; Heinze et al., 1999; Qin et al., 
2002). The p53 protein functions as a transcription factor by shuttling between the 
nucleus and the cytoplasm. Qin et al. (2002) have also demonstrated that the 3-year and 
5-year overall survival rate of HCC patients with positive p53 nuclear accumulation were 
much lower than those with negative p53 expression suggesting that the p53 mutation or 
nuclear accumulation of p53 expression could be a valuable marker for predicting the 
prognosis of HCC patients after resection. Other factors such as mdm2 that interacts and 
regulates p53 degradation may also potentially serve the same function as a molecular 
biomarker for HCC (Endo et al., 2000). The pathogenesis of HCC is a multi-gene 
process. Thus, the use of a single biomarker could not provide a reliable prediction. A 
combination of biomarkers may provide more accurate diagnosis/prognosis of the 
disease.    
1.4 Renal Cell Carcinoma (RCC) 
The genetic basis of kidney cancer has been relatively well established with the 
identification of genes involved in each histological type of tumour. These histological 
types include clear cell, Type I papillary RCC, Type II papillary RCC, and chromophobe 
RCC and oncocytoma. The genetic basis of these different kidney cancers and potential 
biomarkers for RCC will be highlighted. 
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1.4.1 Epidemiology and Etiology of Renal Cell Carcinoma 
Renal cell carcinoma (RCC) is the most common malignant tumour of the adult 
kidney, accounting for around 3% of human malignancies (Belldegrum and DeKernion, 
1998). The incidence of RCC is increasing, and it is estimated that RCC accounts for 
95,000 deaths per year worldwide (Vogelzang and Stadler, 1998). In the United States, 
kidney cancer affects nearly 32,000 individuals and is responsible for over 12,000 deaths 
each year (Linehan et al., 2001a; Landis et al., 1999). It is estimated that 200,000 
individuals are living with kidney cancer in the U.S. Since 3 decades ago, kidney cancer 
has increased at a rate of about 2.5% per year in the U.S. with the highest rates of 
increase observed in African Americans. Between 1975 and 1995 RCC incidence rates 
increased annually 2.3% in white men, 3.1% in white women, 3.9% in black men and 
4.3% in black women (Chow et al., 1999). Prognosis is significantly better in women 
than in men for clear cell RCC (Sejima and Miyagawa, 1999). The consistently higher 
incidences in women and better prognosis indicate that gender difference may influence 
the development of RCC. 
Numerous studies have been performed to identify the risk factors for the 
development of RCC. Tobacco smoking, hypertension/anti-hypertensive medications, 
obesity, and family history have been identified as the major risk factors for the 
development of RCC. The population attributable risk for hypertension was 21%, obesity 
at 21 %, and smoking at 18%. Among all reported cases, at least 40% of the RCC cases 
were not explained by the risk factors studied (McLaughlin and Lipworth, 2000).  
Kidney cancer is not a single disease but comprises of several cancers occurring 
in this organ (Chow et al., 1999; Linehan et al., 2001a; Linehan et al., 2002). The most 
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common histological types of kidney tumours are clear cell (75%), Type I papillary RCC 
(~5%), Type II papillary RCC (~10%), and chromophobe RCC and oncocytoma (~10%). 
These different types of kidney cancer may have markedly differing clinical courses 
leading to different responses in therapy and could be attributed to different genes 
(Linehan et al., 2001b; Linehan et al., 2002). However, approximately 3-5% of RCC 
cases are morphologically unclassified (Kovacs et al., 1997). This type of tumour is 
generally larger, more aggressive, high grade with unrecognisable cell types without 
typical renal cell epithelial components and is associated with poor clinical outcomes. 
The overall median survival in patients with unclassified RCC is only 4.3 months 
(Zisman et al., 2002).    
1.4.2 Genetic basis of kidney cancer 
The genetic basis of RCC was established by studying the hereditary forms of 
RCC. Genetic mapping and positional cloning enabled the identification of tumour 
suppressor gene(s) and oncogene(s) involved in the manifestation of RCC. Mutation or 
loss of these genes has also been demonstrated in the sporadic forms of RCC. To date, 
four types of inherited epithelial forms of renal carcinoma have been delineated 
clinically, and genes responsible for them have been characterized. Each disease has 
distinct clinical features, and is caused by mutation in a distinct gene. The four well-
described types of inherited kidney cancer are von Hippel-Lindau (VHL), hereditary 
papillary renal carcinoma (HPRC), hereditary leiomyoma renal cell carcinoma (HLRCC) 
and Birt-Hogg-Dubé (BHD) syndrome. VHL is an inherited form of clear cell RCC, 
HPRC is a hereditary form of Type I papillary RCC, HLRCC is Type II papillary RCC 
and individuals affected with BHD are at risk of developing several types of renal 
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tumour, including chromophobe RCC and oncocytoma (Kirkali and Lekili, 2003; 
Linehan et al., 2003; Linehan and Zbar, 2004; Linehan et al., 2005). 
1.4.2.1 von Hippel-Lindau (VHL) 
Individuals with VHL are at risk for the development of tumours in a number of 
organs, including the kidneys, pancreas, adrenal glands, brain, spine, eye, and inner ear 
(Linehan et al., 2001; Linehan et al., 2002). Approximately 35% to 45% of individuals 
affected with VHL developed RCC of the clear cell histology (Glenn et al., 1990) and 
these are often early onset tumours. Partial deletion of the VHL gene or mutation that 
shorten VHL protein is often detected in the renal tumours derived from these patients 
(Linehan et al., 1995; Linehan et al., 2002; Lubensky et al., 1996). Walther et al (1995) 
estimated that as many as 600 microscopic clear cell neoplasma and 1,100 cysts may 
develop in an average VHL kidney and these tumours are malignant tumours that can 
metastasize.  
Glenn (1992) and Latif et al (1993) reported the identification of the VHL gene, 
which resides on the chromosome 3p25. VHL mutations have been found in high 
percentages of VHL kindreds (nearly 100%) (Stolle et al., 1998), including intragenic 
mutation (frameshift, missense, nonsense, etc.), partial and complete deletions of the 
gene, splicing mechanism defects (Linehan et al., 2005), DNA hypermethylation 
(Herman et al., 1994), and chromosome 3 translocations (Koolen et al., 1998; Bodmer et 
al., 1998; Van Kessel et al., 1999). VHL germline mutation testing can now be used to 
identify at-risk individual affected by VHL. In sporadic non-inherited kidney cancer, 
mutations of the VHL gene were found in high percentage of patients with clear cell 
RCC, but not in tumour from patients with papillary RCC, chromophobe RCC or 
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oncocytoma (Gnarra et al., 1994; Shuin et al., 1994). These studies provided the initial 
foundation for genetic classification of kidney cancer. 
VHL exists as a tumour suppressor gene and encodes for two protein isoforms 
due to translational initiation from two alternative in-frame AUGs (Schoenfeld et al., 
1998; Iliopoulos et al., 1998; Blankenship et al., 1999). Both isoforms are capable of 
suppressing RCC growth in vivo and could shuttle to and forth between nucleus and 
cytoplasm, and associate with the endoplasmic reticulum and mitochondria (Iliopoulos et 
al., 1995; Duan et al., 1995; Lee et al., 1999a; Shiao et al., 2000; Schoenfeld et al., 2001; 
Groulx and Lee, 2002). VHL protein serves to target specific proteins such as members 
of the hypoxia-inducible factor (HIF)  family, for destruction. HIF1- is a transcription 
factor that controls the transcription of a number of downstream genes, such as VEGF, 
PDGF, TGF-, the glucose transporter (GLUT1) and erythropoietin.  Loss of function or 
expression of the VHL protein leads to the accumulation of HIF1- protein, with 
subsequent over-expression and increase level of these growth factors, which can 
promote renal cell growth and proliferation. The above mechanisms were extensively 
reviewed earlier (Kirkali and Lekili, 2003; Linehan et al., 2003; Linehan et al., 2005; 
Linehan and Zbar, 2004; Kaelin, Jr., 2004).                      
1.4.2.2 HPRC, HLRCC and BHD 
HPRC is a hereditary cancer syndrome in which those affected are at risk of 
developing bilateral, multifocal Type I papillary RCC (Zbar et al., 1994; Zbar et al., 
1995). This disease is highly penetrant and tumour is uniformly of Type I papillary 
histological type (Lubensky et al., 1999). HPRC patients are at risk of developing up to 
3,000 tumours per kidney (Ornstein et al., 2000) and the kidney is the only organ that is 
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affected. These tumours usually appear later in life (in the fifth and sixth decade) and 
often are very well differentiated, malignant and can metastasize (Linehan et al., 2005).  
Genetic linkage analysis located the gene responsible for HPRC to the long arm 
of chromosome 7, where the proto-oncogene, c-Met was found (Schmidt et al., 1997; 
Schmidt et al., 1998). Met encodes for the surface receptor for the ligand HGF. A 
germline mutation found in tyrosine kinase domain of the Met gene leads to constitutive 
activation of the receptor in papillary renal carcinoma (Schmidt et al., 1998). Mutations 
of the Met gene were also found in a subset of sporadic, non-inherited Type I papillary 
renal carcinoma.      
Similarly, HLRCC is linked to the loss of fumarate hydratase (FH), which is a 
Krebs cycle enzyme (Tomlinson et al., 2002). Germline FH mutations were found in 31 
of 35 HLRCC kindreds (Toro et al., 2003). Affected individuals are at risk of developing 
cutaneous and uterine leiomyomas and papillary RCC (Launonen et al., 2001). Kidney 
tumours derived from patients with HLRCC tend to be unilateral and solitary. They are 
primarily Type II papillary RCC; often very aggressive and appear to metastasize early 
(Linehan et al., 2005).  
Mutations were suspected to be responsible for the inactivation of BHD gene, 
which may be a potential tumour suppressor gene (Nickerson et al., 2002; Linehan et al., 
2003) localized on the short arm of chromosome 17 (Schmidt et al., 2001; Khoo et al., 
2001). Individuals with BHD are at risk of developing fibrofolliculoma, pulmonary cysts 
and renal tumour (Birt et al., 1977; Toro et al., 1999; Zbar et al., 2002). BHD patients can 
develop renal tumours that are bilateral and multifocal; and are malignant and highly 
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metastastic. The renal tumours in BDH are predominantly chromophobe RCC, oncocytic 
neoplasms and oncocytoma (Pavlovich et al., 2002).  
1.4.3 Molecular biomarkers for renal cell carcinoma 
Patients with localized kidney cancer have an excellent prognosis as compared to 
those with advance disease. Five and 10-year survival is 95% for stage I, 88% and 81% 
for stage II, and 59% and 43% for stage III, respectively, while those presented with stage 
IV RCC have only 20% 5-year and 14% 10-year survival (Javidan et al., 1999). Complete 
surgical resection is considered to be the only effective treatment for patients with 
clinically localized RCC. However, the disease recurs postoperatively in 20%-40% of 
patients who undergo potentially curative nephrectomy (Belldegrum and DeKernion 
1998). Accurate prediction of long-term cancer-free survival immediately after resection 
of clinically localized diseases, therefore, will be valuable for planning follow-up 
protocols and for identifying patients with a high risk of recurrence and for patients who 
would benefit the most from adjuvant therapy. Although conventional prognosis factors 
such as pathologic tumour stage and grading are useful, other novel prognostic 
parameters, including clinical, laboratory, and biomolecular factors, are needed to 
provide additional predictive value (Mejean et al., 2003). 
Besides providing prognostic information (risk of recurrence or metastasis), 
tumour markers could also hold the key to targeted therapeutic intervention. Currently, 
many markers related to tumour proliferation, growth, angiogenesis, loss of cell adhesion 
and hypoxia-inducible factor among others, are being evaluated for their prognostic 
value. These biomarkers include proliferating cell nuclear antigen (PCNA), laminin, Ki-
67, silver-stained nucleolar organizer region (AgNOR) counts, p53 mutations, over-
  LITERATURE REVIEW 
________________________________________________________________________ 
 33
expressed growth factors, metallothionein, and increased micro-vessel density (Delahunt 
et al., 1993; Yoshida et al., 1994; MacLennan and Bostwick, 1995; Aaltomaa et al., 1997; 
Sejima and Miyagawa, 1999; Kirkali et al., 2001; Tuzel et al., 2001). However, none of 
these factors appears to be a better predictive prognostic marker than the usual staging 
and grading.  
Other serum markers such as VEGF, interleukin (IL)-12, the soluble IL-2 
receptor, and intercellular adhesion molecule-1 have been shown to have a prognostic 
value, but no specific serum markers for RCC are yet available (Hoffmann et al., 1999; 
Kallio et al., 2001). High levels of preoperative hCG  subunit may identify patients with 
increased risk of progression (Hotakainen et al., 2003), while high expression level of 
IGF-I receptor may predict poor survival among patients with RCC (Parker et al., 2002). 
Cadherin-6 has recently been shown to be a useful molecular marker to detect the 
circulating cancer cells disseminated from conventional RCC (Li et al., 2005). Similarly, 
CD70, a type II transmembrane protein belonging to tumour necrosis factor family, has 
been identified as a new specific tumour marker for clear cell RCC (Junker et al., 2005). 
Carbonic anhydrase (CA) 9, a member of the CA family thought to have a role in the 
regulation of intra- and extracellular pH during the period of hypoxia in tumour cells, 
have gained recent interest. Low CA9 staining was found to be an independent prognostic 
indicator of poor survival in patients with metastatic RCC and in low-grade and stage 
tumour (Bui et al., 2003; Soyupak et al., 2005).  
Recently, Kim et al (2005) have demonstrated in patients with clear cell RCC that 
the use of 8 molecular markers in a prognostic model for survival is more accurate than a 
standard clinical model using the combination of stage, histological grade and 
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performance status. The markers used include Ki-67, p53, gelsolin, CA9, CA12, PTEN 
(phosphatase and tensin homologue deleted on chromosome 10), epithelial cell adhesion 
molecule and vimentin. The incorporation of molecular tumour marker into future staging 
systems is expected to revolutionize the approach to diagnosis and prognosis (Bui et al., 
2001; Lam et al., 2005). 
1.5 Human chorionic gonadotropin, Pregnancy and Cancer 
The influence of hCG on cancer growth and development is highly controversial. 
On one hand, the hCG hormone has been demonstrated to confer protection against 
mammary carcinogenesis (Russo et al., 2005), altering the course and preventing the 
formation of granulosa cell tumour in CF-1 mice predisposed to tumour formation 
(Owens et al., 2002). On the other hand, hCG, particularly the  subunit, is over-
expressed in a relatively high proportion of both the trophoblastic (i.e. hydatidiform 
mole, choriocarcinoma, placental site trophoblastic tumour, etc.) and non-trophoblastic 
tumours (i.e. bladder cancer, renal cancer, breast cancer, etc.) (Stenman et al., 2004). 
Elevated level of hCG  subunit is usually a sign of aggressive disease and is strongly 
associated with poor prognosis. Thus, it appears that the response of cancer to hCG may 
depend on the amount and timing of hCG application.       
1.5.1 Functions of Human chorionic gonadotropin (hCG)  
The glycoprotein hormone family comprises of chorionic gonadotropin (CG), 
luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating 
hormone (TSH). All members are heterodimers consisting of an  and  subunit. The  
subunit of 92 amino acids is common to all glycoprotein hormones. The biological 
  LITERATURE REVIEW 
________________________________________________________________________ 
 35
activity is determined by its  subunit, which displays extensive homology (80%) 
between the hCG and LH.  
The CG hormone is essential for normal reproductive function (Pierce and 
Parsons, 1981) and acts to maintain high progesterone levels during pregnancy (Segaloff 
and Ascoli, 1993). Both the LH and CG stimulates the production of gonadal steroid 
hormones via its interaction with the lutropin-choriogonadotropin-receptor (LH-CG-R) 
present in the granulosa cells of the ovary and in the testicular Leydig cells (McFarland et 
al., 1989). Upon binding of CG to its receptor, adenylyl cyclase activity is elevated 
through an intracellular membrane-associated G protein-coupled mechanism that results 
in an increase in cAMP levels, leading to the synthesis of steroid and polypeptide 
hormones (McFarland et al., 1989). Jiang et al. (2002) have shown that hCG and inhibin 
induce histone acetylation in human breast epithelial cells, which could be an alternative 
route of gene regulation.  
1.5.2 Protective effects of hCG and Pregnancy against mammary 
carcinogenesis  
The protective effects of hCG and pregnancy against mammary carcinogenesis 
have been well established. Women who have their first pregnancy after 30 years of age 
have a 2-5 fold higher lifetime risk of developing breast cancer compared to those whose 
first pregnancy occurs before 20 years of age (MacMahon et al., 1970; Trichopoulos et 
al., 1983). The protective effect of pregnancy against the development of cancer is 
believed to be attributed by an increase in cellular differentiation and the reduced rate of 
cell proliferation in the mammary epithelium (Dickson and Lippman, 1995). Russo et al 
(1990a, 1990b, 1991) demonstrated that 7, 12-dimethylbenz (a) anthracene (DMBA)-
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induced mammary carcinogenesis in the female rat is effectively inhibited by either 
pregnancy or human chorionic gonadotropin (hCG) treatment. The protective effect of 
hCG on the development of mammary tumours has been variously attributed to: 
induction of differentiation, inhibition of cell proliferation, increase in DNA repair 
capabilities, induction of inhibin by the mammary epithelium, activation of programmed 
cell death, and down-regulation of IGF-I and IGF-I receptors in mammary epithelial cells 
(Russo et al., 1990a; Russo et al., 1990b; Russo et al., 1991; Alvarado et al., 1994; 
Srivastava et al., 1997; Huynh, 1998). 
Russo et al (2005) have also recently deciphered the genomic signatures that 
confer the long-term protection by pregnancy and hCG treatment against mammary 
carcinogenesis.  The authors demonstrated that short-term treatment with recombinant 
hCG could induce the same genomic signature as the reproductive process, inhibiting not 
only the initiation but also the progression of mammary carcinogenesis, stopping the 
development of early lesions, such as intraductal proliferations and carcinoma in situ. 
These observations indicate that short-term hCG treatments provides a novel strategy in 
breast cancer prevention (Russo and Russo, 1994; Russo and Russo, 2000). Although 
much have been known about the effects of hCG on mammary gland, other important 
novel mechanisms involved in this complex process are yet to be discovered. 
1.5.3 Granulosa cell tumours 
The ovary is a dynamic organ that undergoes specific changes in response to the 
pituitary gonadotropins FSH and LH (Richards, 1994; Rinehart et al., 2004) and ovarian-
derived factors to support follicle growth, ovulation, and luteinization. Ovarian granulosa 
cells undergo a complete differentiation process during the growth and maturation of 
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ovarian follicles. This process includes the acquisition of FSH-R in the early stages of 
follicular growth, and the induction of FSH-R and LH-CG-R in granulosa cells which is a 
critical step in reproductive physiology. Owen et al (2002) have demonstrated that 
administration of surges of hCG that mimic ovulatory levels of LH block the formation of 
granulosa cell tumours in genetically predisposed mice while triggering formation of 
luteomas. This switch of pathway from tumour to luteomas formation may be attributed 
to the sudden increase of hCG that is necessary for granulosa cell differentiation (i.e. 
during preovulatory). These observations suggest that surge in hCG may have protective 
function against granulosa cell carcinoma. 
Granulosa cell tumours are rare and comprises of only 10% of all ovarian tumours 
(Cooke et al., 1995; Wynder et al., 1969). The clinical importance of this type of cancer 
was attributed to its potential for malignancy and recurrence (Wynder et al., 1969; Cooke 
et al., 1995; Fontanelli et al., 1998; Lee et al., 1999b). Altered expression of genes 
associated with granulosa cell tumours includes; inhibin (Lappohn et al., 1989; Burger et 
al., 1998; Robertson et al., 1999a; Robertson et al., 1999b), p53 (Gebhart et al., 2000), c-
erB2, c-myc, and several others (King et al., 1996; Owens et al., 2002). Hormonal 
alterations also play a role in the development of granulosa cell tumours. Mice lacking 
the FSH-R and those that hypersecrete LH develop granulosa cell tumours, which could 
be due to elevated levels of gonadotropins (Risma et al., 1995; Danilovich et al., 2001). 
The complex interplay between hormonal regulation and gene alterations in granulosa 
cell tumours has provided a complex scenario to the disease process.      
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CHAPTER 2: INTRODUCTION 
2.1 The isolation of OKL38 
Growth factors and inhibitors play crucial roles in the growth regulation of cell 
proliferation and differentiation of mammary epithelial cells. Studies have shown that 
during pregnancy, with the onset of terminal differentiation, there is a dramatic decrease 
in the proliferation of the mammary epithelial cells. This is one of the hypothesized 
reasons for pregnancy protection of mammary gland against carcinogen insults. With the 
notion to isolate and characterize genes that are differentially regulated during pregnancy 
and potentially involved in this protection mechanisms, differential display was 
performed using mRNA from mammary gland of non-pregnant and 18-days pregnant 
rats. Among the 18 differentially expressed bands, a novel 450-bp DNA fragment, which 
was up-regulated in the pregnant animals, was identified. This novel gene is ubiquitously 
expressed in all rat tissues with the highest levels detected in the ovary, kidney and liver. 
The human cDNA of 1.6 kb was isolated from human ovarian library and later named 
OKL38 (Ovary Kidney Liver 38 kDa) (Huynh et al., 2001).  
2.2 Pregnancy induced OKL38 expression 
The expression of OKL38 in rat mammary gland at different stages of pregnancy 
and lactation was previously demonstrated (Huynh et al., 2001). OKL38 transcripts were 
up regulated during pregnancy and lactation in the rat mammary gland, with the highest 
level of expression during lactation, which coincided with maximal breast epithelial 
differentiation. The transcripts were also localized to the secretory epithelial cell of the 
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mammary gland during this period. These observations documented the existence of a 
certain degree of hormonal regulation in the expression of OKL38.    
2.3 OKL38, a novel growth-inhibitor lost in cancer 
Abnormal expression of the various growth factors and growth inhibitors has been 
implicated in tumourigenesis. Low levels of OKL38 transcripts are observed in various 
human breast cancer cell lines and barely detectable in DMBA-induced rat mammary 
tumours (Huynh et al., 2001). Transfection of MCF-7 cells with OKL38 cDNA resulted 
in growth inhibition in vitro and reduction in tumour formation in vivo, suggesting that 
OKL38 may play a vital role in the growth regulation and differentiation of breast 
epithelial cells during pregnancy and tumourigenesis (Huynh et al., 2001). The molecular 
mechanisms by which OKL38 exerts its role in growth inhibition and differentiation are 
still unknown.  
2.4 Scope of this study 
The novelty and significance of OKL38 in cancer prompt further investigations 
into the functions and regulations of this important gene. The objectives of this thesis 
include: (1) Cloning, sequencing and characterization of the human OKL38 gene; (2) 
Establishing a rat model to characterize the functions and regulations of OKL38 via 
cloning the rat homologs of OKL38; (3) Using the rat model to study the regulatory 
effect of hCG and pregnancy on OKL38 in both the mammary gland and ovary;  (4) 
Investigating the expression profile of OKL38 in kidney and liver cancer, determining the 
potential use of OKL38 as a biomarker; (5) Identifying the mechanisms involved in the 
loss of OKL38 expression in cancer. 
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CHAPTER 3: MATERIALS AND METHODS 
3.1 Reagents 
Horseradish peroxidase-conjugated donkey anti-mouse or anti-rabbit secondary 
antibodies were purchased from Pierce, Rockford, Illinois. Chemiluminescent detection 
system was supplied from Amersham, Pharmacia Biotech, Arlington Heights, IL. Tissue 
culture dishes were purchased from Nunc Inc. Naperville, IL. High glucose Dulbeccos 
Modified Eagle Medium (Hi-Glu-DMEM), Alpha Modified Eagle medium (-MEM), 
Fetal bovine serum (FBS), Lipofectamine 2000 reagent and penicillin-streptomycin 
(PS) were from Invitrogen, Carlsbad, CA. The human CG used in this study was 
purchased from Profasi, Laboratoires Serono S. A., Aubonne, Switzerland. 
3.2 Animals 
Animal were maintained and treated according to the protocol approved by the 
institutional animal care committee. Twenty-four female Sprague-Dawley rats (fifty days 
old and weighing approximately 250g) were divided into 4 equal groups. Each group (n = 
6) received daily intraperitoneal (IP) injection of either phosphate buffer saline (PBS) or 
3 different doses of hCG (10, 20 and 40 UI in 200 µl of PBS) for 21 days. After the last 
injection, the rats were allowed to rest for an additional 2 days before they were 
sacrificed. The ovary, kidney, liver and mammary gland were harvested, frozen in liquid 
nitrogen and stored at 80oC. 
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3.3 Probe labelling 
All probes used for library screening as well as for Southern and Northern blot 
analyses were radioactively labelled with  [32p]deoxy-CTP (ICN, Costa Mesa, CA) 
using the Rediprime II DNA Labelling System (Amersham, Pharmacia Biotech, 
Arlington Heights, IL) as described by the manufacturer. Unincorporated nucleotides 
were removed using a nucleotide purification kit (Qiagen, GmbH, Hilden, Germany). 
3.4 Screening, Subcloning and Sequencing of the human 
OKL38 gene 
Two cosmid clones containing human OKL38 gene were isolated from the human 
cosmid library (Clontech, Palo Alto, CA) employing the human OKL38 cDNA as probe 
(Huynh et al., 2001). Restriction digestion and Southern blot analysis were used to 
estimate the genomic DNA insert size and confirmation of their identity. Shotgun 
strategy was adopted to subclone the cosmid insert for sequencing. In brief, the cosmid 
clone was digested with various restricted enzymes, single or double digestion. The 
digested products were separated on an agarose gel and products less than 6 kb were 
cloned into pBluescriptSK (Stratagene, La Jolla, CA) vector with the sub-cloning map 
shown in figure 4.1A. All subclones and cosmid clones were subjected to complete 
sequencing via direct cosmid sequencing and the use of Template Generation System 
(Finnzymes, Finland) as recommended by the manufacturer. Sequencing of the CCCT 
rich region resided in subclone Bs/X-1.1 (Fig. 4.1A) was attempted using the 
SequenceRx enhancer solution F (Gibco, Grand Island, NY). The GenomeWalker kit 
(Clontech, Palo Alto, CA) was used to clone and characterize the 3-end of OKL38 gene 
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using the GW-F forward primers (Table 2) as described by the manufacturer. All 
sequencing was performed using automated sequencing via the modified dideoxy chain 
termination using the BigDye version 3.0 (Applied Biosystem, Foster city, CA). All the 
DNA inserts concerned were sequenced to a redundancy of 3 times. 
3.5 Rapid Amplification of cDNA Ends (RACE) Analysis 
To establish the full-length cDNA of human OKL38, 5RACE was performed 
using the SMART RACE cDNA amplification kit (Clontech, Palo Alto, CA) according 
to the manufacturers direction with the following modifications: The secondary PCR of 
the primary RACE products was performed using Advantage Genomic polymerase 
(Clontech, Palo Alto, CA). Gene-specific primer, GSP1R (Table 2) was designed based 
on the 5end sequence of the previously isolated human OKL38 cDNA (Huynh et al., 
2001), while GSP2R was designed based on the 5end sequence of the GSP1R race 
fragment (Fig. 4.4A).  The RACE products were identified using Southern blot analysis 
and subsequently cloned into pCR-Blunt-II-TOPO vector (Invitrogen, Carlsbad, CA) 
and sequenced using T7 and SP6 primers. Sequence analysis was carried out using Laser 
gene sequence analysis software (Dnastar Inc, Madison, WI). 
The same strategy was also used to establish the full-length cDNA of rat OKL38. 
Gene-specific primer, 1R (Table 4) was designed based on the 5end sequence of the 
isolated rat OKL38 cDNA. The RACE products were subsequently cloned into pCR-
Blunt-II-TOPO vector (Invitrogen, Carlsbad, CA) and 5 positive clones from each 
fragment were sequenced using T7 and SP6 primers. Sequence analysis was carried out 
as described above. 
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3.6 Primer Extension Study 
To identify the transcriptional start site of OKL38 gene, primer extension study 
was performed. Two µM of 32P-labelled primer (Pext1 on exon1 and Pext3 on exon3) 
(Table 2) were allowed to hybridized with 200 ng of human liver, kidney and prostate 
poly (A)+ mRNA (Clontech, Palo Alto, CA). Touchdown methodology was employed to 
increase the stringency of hybridization with the following parameter: 85oC, 15 min; 
84oC, 90 s; -0.1oC for every subsequent cycle to dock at a final temperature of 50oC. The 
hybridization mix was added to the reverse transcription mix to a total volume of 100 µl 
containing 5X Superscript buffer, 0.1 M DTT, 10 µM dNTP, 250 U Superscript II 
enzyme (Invitrogen, Carlsbad, CA), Rnasin (Promega, Madison, WI), diethyl 
pyrocarbonate water (DEPC-H2O) and followed by extension for 1 hr. The reaction was 
terminated by heating to 70oC for 15 min, ethanol precipitated, dried, redissolved in 
formamide-dye mix, and run on a 6% denaturing gel. The fmol cycle sequencing kit 
(Promega, Madison, WI) was used to generate DNA ladder with subclone P-3.4 and S-
5.5 (Fig. 4.1A) as template, and Pext1 and Pext3 as primers, respectively. 
3.7 Cloning of OKL38 cDNAs 
3.7.1 Cloning cDNA of HuOKL38 - 1a, 2a and 2b cDNA 
Cloning of the full length cDNA of the HuOKL38-1a transcript was achieved 
using two PCR primers, forward primer 1F (nucleotide position 7-33) designed at the 5 
end and reverse primer 1R (nucleotide position 1863-1889) (Table 2) designed at the 3-
end of the HuOKL38-1a cDNA. To clone the HuOKL38-2a and -2b cDNAs, forward 
primer 2F (nucleotide position 52 to 75 of -2a transcript) (Table 2) was used (Fig. 4.9A).  
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In all cases, the forward primer carried a HindIII and the reverse primer an EcoRI 
restriction site for directional cloning. To generate the cDNA template for PCR cloning, 1 
µg of human liver mRNA was reversed transcribed using SuperScriptII reverse 
transcriptase (Invitrogen, Carlsbad, CA) as recommended by the manufacturer. The 
template was amplified by PCR under the following conditions: denaturation step at 94oC 
for 2 min, followed by 35 cycles of 94oC for 1 min, 60oC for 1 min, 72oC for 2 min and 
30 sec, and a final extension at 72oC for 5 min.  PCR products of the correct size were 
cloned into pBluescriptSK (Stratagene, La Jolla, CA) for sequencing. 
3.7.2 Cloning of RtOKL38-2.0, -2.3 and -2.3A cDNAs 
Four rat OKL 38 cDNAs of approximately 1.1 kb were isolated from screening rat 
liver cDNA library using the human OKL38 cDNA as a probe. Cloning of the full length 
cDNA of the RtOKL38-2.0 transcript was achieved using two PCR primers, forward 
primer FL-2.0F (nucleotide position 12-34) designed at the 5 end and reverse primer FL-
2.0R (nucleotide position 1937-1959) (Table 4) designed at the 3-end of the 2.0 cDNA. 
To clone the RtOKL38-2.3 and -2.3A cDNAs, forward primer FL-2.3F (nucleotide 
position 6-30 of 2.3 transcript) (Table 4) was used instead of the FL-2.0F primer (Fig. 
4.20).  In all cases, the forward primer carried a HindIII and the reverse primer a NotI 
restriction site for directional cloning. To generate the cDNA template for PCR cloning, 1 
µg of rat kidney poly(A)+ mRNA was reversed transcribed using SuperScriptII reverse 
transcriptase (Invitrogen, Carlsbad, CA) as recommended by the manufacturer. The 
template was amplified by PCR as described for cloning the human cDNAs and PCR 
products of the correct size were cloned into pBluescriptSK (Stratagene, La Jolla, CA, 
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USA) and sequenced. Two more internal primers, 2R and 3R (Table 4) were also utilized 
for sequencing. 
Due to the low expression level of the RtOKL38-2.3A transcript, additional 
secondary PCR was performed for its cDNA isolation. After PCR amplification, the 
region below the 2.3 kb band (approximately at the 2.2 kb position on the agarose gel) 
was purified (Qiagen, GmbH, Hilden, Germany) and the extracted DNA was subjected to 
a second round of PCR amplification under the same conditions. A 2.2 kb fragment was 
obtained, cloned and sequenced as described above.  
3.8 In Vitro Transcription and Translation (TNT) Study 
3.8.1 Coupled TNT for human OKL38 variants 
To verify the predicted molecular weight of the putative ORF of human OKL38, 
the TNT Coupled Reticulocyte Lysate System (Promega, Madison, WI) was used to 
transcribe and translate the HuOKL38-1a, -2a, -2b and the previously cloned 1.6 kb 
cDNA according to the manufacturers instruction. Briefly, the cloned cDNAs in 
pBluescriptSK (Stratagene, La Jolla, CA) were digested with EcoRI (New England 
Biolabs, Beverly, MA) and extracted twice with phenol/chloroform. The DNA was 
precipitated with ethanol, washed with 70% ethanol, air-dried and resuspended in H2O. 
One µg of the digested plasmid was used for the in vitro TNT reaction. The synthesized 
protein was labelled with [35S] L-Methionine (ICN, Costa Mesa, CA) and 5 µl of the 
reaction was loaded and electrophoresed on a 10% SDS-PAGE. The synthesized 
protein was transferred onto a nitrocellulose membrane and auto-radiographed to film. 
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The identity of the in vitro synthesized protein was confirmed via Western blot using 
rabbit anti-Human OKL38 antibodies.  
3.8.2 Coupled TNT for rat OKL38 variants 
To verify the predicted molecular weight of the putative ORF of rat OKL38 
variants, the TNT Coupled Reticulocyte Lysate System (Promega, Madison, WI) was 
used to transcribe and translate the RtOKL38-2.0, -2.3 and -2.3A cDNAs according to 
the manufacturers instruction. Same TNT procedures were performed as described for 
the human OKL38 cDNAs with some modification: The constructs were digested with 
NotI and 0.4 pmol of the digested plasmid was used for the TNT reaction. Western blot 
analysis was performed on the TNT products using rabbit anti-Rat OKL38 antibodies. 
3.9 Multiple Tissue Expression Array, Northern Blot Analysis 
and Cancer Profiling Array 
The Multiple Tissue Expression (MTE) and Cancer Profiling Array (CPA) were 
purchased from Clontech (Clontech, Palo Alto, CA) and the human Northern blots were 
from Invitrogen (Invitrogen, Carlsbad, CA). Both the arrays and blots were hybridized 
with a 700 bp SmaI human OKL38 probe (9361685 nt of HuOKL38-1a) that detects all 
the different variants. Ubiquitin (provided by manufacturer) and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH; American Type Culture Collection, Manassas, VA) 
were used for normalizing the arrays and Northern blottings, respectively. Pre-
hybridization of the arrays and blots were performed at 50oC for 1 hour in ExpressHyb 
(Clontech, Palo Alto, CA) with sheared salmon testis DNA added to a final concentration 
of 0.1 mg/ml. The denatured radiolabelled probe was mixed directly into the pre-
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hybridization solution and hybridised overnight at 50oC. After hybridisation, the arrays 
were washed 3 times at 55oC in solution 1 (2x SSC, 0.5% SDS) for 30 min each time, 
repeated with solution 2 (0.2x SSC, 0.5% SDS) and a final rinse in 2x SSC at room 
temperature. Blots were exposed to a phosphor-imager.  As for the Northern blot 
analysis, washing was performed at 45oC using solution 1 and 2. mRNA levels were 
determined by densitometric scanning of autoradiographs and normalised with GAPDH.   
Total RNA for Northern blot analysis was extracted from rat tissues and organs 
using Trizol Reagent (Invitrogen, Carlsbad, CA). The poly (A)+ mRNA was isolated 
from the indicated organs and tissues of female rats using the Oligotex mRNA Kit as 
described by the manufacturer (QIAGEN, GmbH, Hilden, Germany). Northern blot 
analysis was performed on poly (A)+ mRNA or total RNA as described (Huynh et al., 
1993). Blots were hybridized with: 1) rat OKL38 probe (nucleotide position 926-2004) 
that detects all three variants; 2) variant-specific probe (nucleotide position 6-395 of 
RtOKL38-2.3 transcript), which detects only the RtOKL38-2.3 and -2.2 transcripts; or 3) 
GAPDH. The mRNA levels were determined by densitometric scanning of 
autoradiographs and normalised with GAPDH. 
3.10 Semi-quantitative RT-PCR of OKL38 variants 
3.10.1 One-Step RT-PCR for detection of human OKL38 variants 
One µg of total mRNA was used as template for One Step RT-PCR (Qiagen, 
GmbH, Hilden, Germany) adopting the procedure recommended by the manufacturer. To 
study the expression of the HuOKL38-1a transcript, variant-specific forward primer 
PCR-1F (nucleotide position 1-28) and a common reverse primer PCR-1R (Table 2) were 
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designed for RT-PCR. To determine the expression of HuOKL38-2a, -2b and -2c 
transcripts, RT-PCR was performed using the forward primer PCR-2F and reverse primer 
PCR-1R (Table 2). Total amount of OKL38 transcripts in the tissue samples were 
detected using a pair of primers, E7T-F and E8T-R (Table 2), which were designed in 
exon 7 and 8, respectively. The specificity of the designed primers and PCR conditions 
were optimised using the three cloned cDNAs, HuOKL38-1a, -2a and -2b as templates. A 
pair of tubulin primers, TubF (5 AACGTCAAGACGGCCGTGT 3) and TubR (5 
GACAGAGGCAAACTGAGCAC 3), which amplify a 400-bp fragment of tubulin 
cDNA, was used for normalization. The temperature regime of One Step RT-PCR was 
performed as follows: 50oC for 30 min; 95oC for 15 min; followed by (29-38) cycles of 
94oC for 1 min, 60oC for 1 min, 72oC for 1 min, and final extension at 72oC for 5 min. 
The amplified products were separated on a 2.0% agarose gel. 
To determine the abundance of HuOKL38-1a, -2a, -2b and -2c transcripts in HCC 
and ABL, 36 PCR cycles were used, while 29 cycles were used for the detection of the 
total OKL38 transcripts. Optimal cycles were determined for the detection of total 
OKL38 transcripts in transfected Chang Liver cells to avoid the undesired amplification 
of DNA constructs present in the RNA extracts. Combination of 1a/2aORF and 2bORF 
extracted RNA was used as the template for optimization and the cycles used were 17, 
20, 23, 26, 29 & 32. One step RT-PCR was performed as described above for the set of 
reaction with reverse transcription. The reverse transcriptase enzyme activity was 
removed for the set without reverse transcription (Fig. 4.37F) by heating at 95 oC for 
15 minutes and cooled, before adding to the RT-PCR reaction.    
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3.10.2 One-Step RT-PCR for detection of rat OKL38 variants 
100 ng of poly(A)+ mRNA were used as template for One Step RT-PCR (Qiagen, 
GmbH, Hilden, Germany) adopting the procedure recommended by manufacturer. To 
study the expression of the RtOKL38-2.0 transcript, variant-specific forward primer 
RTPCR-2.0F (nucleotide position 24-44) and a common reverse primer 2R (Table 4) 
were designed for RT-PCR. To determine the expression of RtOKL38-2.3 and 2.3A 
transcripts, RT-PCR was performed using the forward primer FL2.3F and reverse primer 
2R (Table 4). The specificity of the designed primers and PCR conditions were optimised 
using the three cloned cDNAs, RtOKL38-2.0, -2.3 and -2.3A as templates. To optimise 
the number of cycles for RT-PCR in order to detect the 3 different variants and to prevent 
an amplification plateau for any one transcript, kidney mRNA (expressing high level of 
all three transcripts) was amplified through 23, 25, 27, 29, 31 and 33 cycles. The optimal 
cycles for detection of the RtOKL38-2.0 transcript were 25, and 31 were the optimal 
cycles for RtOKL38-2.3 and -2.3A transcripts. A pair of tubulin primers, TubF (5 
AACGTCAAGACGGCCGTGT 3) and TubR (5 GACAGAGGCAAACTGAGCAC 3), 
which amplify a 400-bp fragment of rat tubulin cDNA, was used for normalization. The 
One Step RT-PCR was performed as follows: reverse transcription at 50 oC for 30 min; 
activating Taq Polymerase at 95 oC for 15 min; followed by 25 (for RtOKL38-2.0 
transcript) or 31 (for RtOKL38-2.3 and -2.3A transcripts) cycles of 94 oC for 1 min, 60 oC 
for 1 min, 72 oC for 1 min, and final extension at 72 oC for 5 min. The amplified products 
were separated on a 2.0 % agarose gel.  
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3.11 OKL38 Antibodies, Western Blot Analysis and 
Immunohistochemical Analysis 
Rabbit polyclonal OKL38 antibodies were raised against the human OKL38 
specific peptide: CAVEWGTPDPSSCGAQ (amino acid position 200-214); and rat 
OKL38 specific peptide: QMMRDQSILSPSPYEGYRSLPEHQ (amino acid position 343 
to 366). Affinity purified rabbit anti-human OKL38 antibody was diluted in Tris buffer 
saline (TBS, 20 mM Tris, 200 mM NaCl, pH 7.6) containing 0.1% Tween-20 (TBST) at a 
final concentration of 1µg/ml. Western blot analysis was performed by incubating the 
blots with 1:2000 anti-OKL38 antibody overnight at 4oC and washed 3 times with TBST, 
15 min each. Subsequently, the blots were incubated with 1:7500 horseradish peroxidase-
conjugated donkey anti-rabbit secondary antibody for 1 hour. After washing 3 times with 
TBST, 15 min each, the blots were then visualized with a chemiluminescent detection 
system as described by the manufacturer. 
For immunohistochemical analysis, 5 µM thick sections were cut, de-waxed in 
xylene, and then rehydrated as described (Huynh et al., 2002). Antigen retrival was 
performed by boiling the slides in 10 mM citrate buffer pH 6.0 for 20 min. Endogenous 
peroxidase activity was block by 3% hydrogen peroxide in methanol for 30 min. After 
two washes of Tris Buffer Saline (20mM Tris, 200 mM NaCl, pH 7.6) (TBS), the 
sections were pre-incubated with 5% skim milk in TBS containing 0.1% Tween-20 
(TBST) for 15 min to reduce non-specific background staining. The section were washed 
twice with TBST for 5 min and incubated overnight at 4oC, with purified primary antisera 
against human OKL38. Immunohistochemistry was performed using the streptavidin-
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biotin peroxidase complex method according to manufacturers instructions (Lab Vision, 
Fremont, CA) using AEC as the chromogen.   
3.12 In situ hybridisation 
To determine the cell-specific expression of OKL38, in situ hybridization was 
performed using sections derived from mammary tissues and ovaries of controls and 20 
IU hCG-treated rats. To generate sense and anti-sense rat OKL38 probes, a 542-bp 
(nucleotides position 925-1466) of rat OKL38 cDNA (GenBank accession no. 
AY081218) was cloned into the pBluescriptSK plasmid. The plasmid construct was 
linearized and digoxigenin-labeled sense and anti-sense RNA probes were synthesized 
using the digoxigenin RNA labeling kit (Roche Molecular Biochemicals, Indianapolis, 
IN) as described by the manufacturer. Fresh tissues were treated with PBS containing 
0.5% active DEPC for 10 min, embedded in Jung-tissue freezing medium (Leica 
Instruments, Nussloch, Germany) and stored at  80 oC. Serial 7- to 8- µm sections were 
heated at 50 oC for 2 min to immobilise the tissue onto the slide. To minimize nonspecific 
background caused by lipid vesicles, the sections were delipidized for 5 min in 
chloroform, dried at room temperature and fixed in PBS containing 4% 
paraformaldehyde. Prehybridization, hybridization, washing and immunological 
detection were performed as described by Braissant and Wahli (1998). 
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3.13 Generation of OKL38-eGFP-pcDNA3.0 Construct 
3.13.1 Generating human OKL38-eGFP-pcDNA3.0 construct 
The HuOKL38-1a cDNA contained an ORF of 477 amino acids. To fuse this 
OKL38 protein to the eGFP via PCR, 4 primers namely 477-F, 477-eGFP-R, eGFP-F and 
eGFP-R (Table 2) were designed. Two separate PCR reactions were performed using the 
primer 477-F and 477-eGFP-R to amplify the ORF of OKL38 and primers eGFP-F and 
eGFP-R to amplify the ORF of eGFP. The amplified products from the two PCR 
reactions were then mixed and reamplified using primers 477-F and eGFP-R. The PCR 
reaction was performed as follows: 95oC for 5 min; followed by 25 cycles of 94oC for 1 
min, 55oC for 1 min, 72oC for 2 min, and final extension at 72oC for 5 min. The 
recombinant products were cloned into pCR-Blunt-II-TOPO vector (Invitrogen, 
Carlsbad, CA), screened for orientation and subsequently cloned into pcDNA3.0 
(Invitrogen, Carlsbad, CA) mammalian expression vector. The OKL38-eGFP-pcDNA3.0 
construct was fully sequenced and endotoxin free plasmid for transfection was prepared 
using Maxi-prep kit (Qiagen, GmbH, Hilden, Germany). The positive control eGFP-
pcDNA3.0 was constructed with the same strategy using only the eGFP-F and eGFP-R 
primers for PCR cloning. 
3.13.2 Generating Sense RtOKL38-eGFP- and eGFP-Antisense-
RtOKL38-pcDNA3.0 construct 
The rat OKL38 cDNA contained an ORF of 478 amino acids. The same strategy 
for generating HuOKL38-eGFP was used to generate the RtOKL38-eGFP. To fuse the rat 
OKL38 protein to the eGFP, PCR was performed using 4 primers namely 478-F, 478-
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eGFP-R, eGFP-F and eGFP-R (Table 4). Two separate PCR reactions were performed 
using the primer 478-F and 478-eGFP-R to amplify the ORF of OKL38 and primers 
eGFP-F and eGFP-R to amplify the ORF of eGFP. The amplified products from the two 
PCR reactions were then mixed and reamplified using primers 478-F and eGFP-R. The 
PCR reaction was performed as follows: 95oC for 5 min; followed by 25 cycles of 94oC 
for 1 min, 55oC for 1 min, 72oC for 2 min, and final extension at 72oC for 5 min. The 
recombinant products were cloned into pCR-Blunt-II-TOPO vector (Invitrogen, 
Carlsbad, CA), screened for orientation and subsequently cloned into pcDNA3.0 
(Invitrogen, Carlsbad, CA) mammalian expression vector. As for the eGFP-Antisense-
RtOKL38-pcDNA3.0 construct, the rat OKL38 ORF was inserted in the reverse order 
into the C-terminal of eGFP protein from the eGFP-pcDNA3.0 construct. All the three 
constructs were was fully sequenced and endotoxin free plasmid for transfection was 
prepared using Maxi-prep kit (Qiagen, GmbH, Hilden, Germany). 
3.14 Generation of 5 and 3UTR of HuOKL38-1a, -2a & -2b 
pcDNA3.0 Constructs 
To determine the regulatory functions of 5 & 3UTR of OKL38 variants, 
constructs of the 3 variants with or without UTRs were generated and cloned into the 
mammalian expression vector pcDNA3.0. The intact OKL38 ORF was used as the 
reporter gene for expression study. The full-length of HuOKL38-1a, 2a & 2b cDNAs 
were cloned into mammalian expression vector pcDNA3.0 as described in Section 3.7.1. 
To generate the 1a and 2a5UTR constructs, forward primer 1F and 2F, and a common 
reverse primer ORF-R, were used for PCR amplification with the 1aFL and 2aFL 
constructs as template, respectively (Fig. 4.36). 1a/2a 3UTR and ORF constructs were 
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amplified using a common forward primer, 1aORF-F and the reverse primers 1R and 
ORF-R, respectively. In these instances, the 1aFL construct was used as the template 
(Fig. 4.36). Similarly, the 2b5UTR construct was amplified using forward primers, 2F 
and the reverse primer, ORF-R. The 2b3UTR and ORF constructs were amplified using 
the common forward primer, 2bORF-F and the reverse primers, 1R and ORF-R, 
respectively (Fig. 4.36). The latter 3 fragments were amplified using the 2bFL construct 
as template. The amplified products were cloned into pCR-Blunt-II-TOPO vector 
(Invitrogen, Carlsbad, CA) and sequenced. Clones with the correct sequence were 
subcloned into pcDNA3.0 vector at the HindIII and EcoRI restriction site and sequenced 
again. All primers used for cloning were presented in Table 2.  
3.15 Generation of HuOKL38-1a & -2a 5UTRs-deleted pcDNA3.0 
and pSEAP2-Control Vector constructs 
To determine the regulatory region that is involved in the down regulation of 
OKL38 translation, HuOKL38-1a and 2a 5UTRs-deleted constructs in two different 
reporter systems were generated (Fig. 4.38). The level of protein expression is 
determined by western blot analysis for those construct carrying the intact OKL38 ORF 
as reporter gene, while the secreted alkaline phosphatase (SEAP) detection system was 
used for those constructs carrying the SEAP ORF. The 1aD1, 1aD2, 2aD1, 2aD2 and 
2aD3 pcDNA3.0 constructed were generated via PCR using the respective forward 
primers and the common reverse primer, ORF-R, as described in Table 2. Protein 
expressions from these constructs were detected by Western blot analysis. The same 
constructs carrying SEAP as the reporter gene, including 2aD4, were cloned adopting 
similar strategy, using the common reverse primer, UTR-R instead of the ORF-R. The E4 
  MATERIALS AND METHODS 
________________________________________________________________ 
 55
SEAP-CV construct was generated by annealing 2 long primers, E4-F and E4-R, and 
subsequently cloned in to the pSEAP CV. The levels of SEAP can be detected in the 
tissue culture medium using the Great EscAPe SEAP Detection Kit as described by the 
manufacturer (Clontech, Palo Alto, CA). 
3.16 Screening for mutation in OKL38 gene 
The OKL38 cDNA consisting of exon 3-8 was amplified from total RNA of HCC 
(5, 6, 8, 10 & 17) and liver cancer cell lines (HepG2, Hep3B, Chang Liver and 
PLC/PRF5). Exon 3-7 was amplified using forward primer, 1F and reverse primer, E81R, 
which reside in exon 3 and 8, respectively. Exon 8 was amplified using forward primer, 
E7TF and reverse primer, 1R, which reside in exon 7 and 8, respectively. The amplified 
DNA fragment were separated on a 1.2 % agarose gel and extracted using the Gel 
Extraction Kit (Qiagen, GmbH, Hilden, Germany). Sequencing was performed with 
internal primers, E82R, E81F & E61R and the 4 PCR primers (Table 2) using automated 
sequencing via dideoxy chain termination using the BigDye version 3.0 (Applied 
Biosystems, Foster City, CA). The sequencing results were aligned using the software 
Dnastar (LaserGene) and the results were tabulated in table 6. 
3.17 Cell Culture and Transfection 
Human kidney (A498) and liver (Chang liver) cancer cells, were maintained as 
monolayer cultures at 37oC (5% CO2) in -MEM plus phenol red, supplement with 10% 
FBS and 1% PS. A498 cells were seeded at 2x105 in 100mm culture dishes containing 
cover slip swab with ethanol and grow to 70% confluence prior to transfection. Cells 
were transfected with 10 µg of either eGFP-pcDNA3.0 or OKL38-eGFP-pcDNA3.0 or 
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OKL38-pcDNA3.0 plasmid DNA and 12 µl of Lipofectamine 2000 reagent following 
manufacturers recommendations. Each cover slip was removed at 24, 48, 72, 96 and 120 
hours post-transfection using a sterile forceps. The cover slip with cells were fixed with 
10% formalin, washed with PBS and mount on to slide for observation using microscope 
(Olympus) equipped with epifluorescence optics and appropriate filters for FITC. 
Buffalo Rat Liver (BRL) cells were maintained as monolayer cultures at 37oC 
(5% CO2) in Hi-Glu-DMEM plus phenol red, supplement with 10% FBS, 1% PS. BRL 
cells were seeded at 2x105 in 100mm culture dishes containing cover slip swab with 
ethanol and grow to 70% confluence prior to transfection. Cells were transfected with 10 
µg of eGFP-, RtOKL38-eGFP- or eGFP-Antisense-RtOKL38-pcDNA3.0 plasmid DNA 
and the cover slips were treated and observed as described above.  
The human liver cancer cell lines HepG2, Hep3B, Chang Liver and PLC/PRF5 
cells were obtained from American Type Culture Collection, Manassas, VA and maintained 
as cultures at 37 oC (5% CO2) in Hi-Glu-DMEM plus phenol red, supplement with 10 % 
FBS and 1% PS. Cells were grown to about 80-90 % confluence prior to total protein and 
RNA extraction.  
To determine the regulation of 5UTRs, Chang Liver cells were seeded at 2.5 X 
105 in 100-mm culture dishes and grown to 80-90 % confluence prior to transfection. 
Cells were transfected with 1 pmole of endotoxin-free plasmid DNA constructs and 
Lipofectamine 2000 reagent following the manufacturers recommendations. The cells 
were harvested 24 hours post-transfection, divided into two portions for protein and RNA 
extraction. Endotoxin-free plasmids used for transfection were prepared using the Maxi-
prep kit (Qiagen, GmbH, Hilden, Germany).    
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3.18 Patients and Tissue Samples 
Prior written informed consent was obtained from all patients and the study 
received ethics board approval at the National Cancer Centre of Singapore, the Singapore 
General Hospital as well as the Binh Dan Hospital, Ho Chi Minh City, Vietnam.   
Tissue samples were obtained intra-operatively from tumours and adjacent non-
tumour kidney tissues during resection for kidney tumour at the Singapore General 
Hospital. The samples were snap frozen in liquid nitrogen and stored at 80oC until 
analysis. A similar set of samples was fixed in 10% formalin and paraffin embedded. The 
HCC tissues samples were obtained intra-operatively from tumours and adjacent benign 
liver tissue during liver resection for HCC in 92 patients at the Singapore General Hospital 
and Binh Dan Hospital. 28 of 92 resected samples had single tumour and 64 of 92 had two 
tumours. Twenty-four tumours and its adjacent liver tissues were snap frozen in liquid 
nitrogen and stored at 80oC until analysis. The samples were fixed in 10% formalin and 
paraffin embedded. The diagnosis of HCC was confirmed histologically in all cases. The 
kidney samples used in this study were also treated the same way. All the kidney tumours 
were of the clear cell histological type. 
3.19 Staging and scoring in HCC 
Staging of tumours was performed using the TNM system (Spiessl B et al., 1992). In 
addition, every tumour was examined macroscopically and microscopically for the presence 
of capsule formation, satellite, multiplicity and necrosis. Dysplasia and cirrhosis in the 
surrounding liver tissue were noted. 27 of 92 tumours were associated with cirrhosis. Within 
27 cirrhotic HCCs, 24 of them had dysplastic tissue. Multifocality was defined as multiple 
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small uniformly sized tumours that were likely represented independent primary tumour 
(Ishak KG et al., 2001). This is distinguished from satellites, which were defined as tumour 
nodules, smaller than main tumour mass, located within a maximum distance of 2 cm. The 
term multiplicity was used for both multifocal tumours and for multiple intra-hepatic 
metastasis from a single primary tumour that were situated further than 2 cm from the edge 
of the main tumour mass. 
The scoring for immunostainning in HCC using OKL38 antibody was described 
below. Tumour sections were considered negative if staining was absent or present in less 
than 5% of tumour cells. The immunostainning was scored using the formula IS = (i+1) * 
PI as described (Claudio et al., 2002), where i = intensity of staining varying between 1+ 
and 5+, and PI = % of positive cells. At least 20 high-power fields were chosen 
randomly, and 2000 cells were counted. Weak, Average and strong staining of OKL38 
expression in carcinoma cells was considered when the IS were in between 20 to 100, 
104 to 240 and 244 to 400 respectively. 
3.20 Computational and statistical Analysis 
Sequence identity and the ORF prediction were done using analysis software from 
the National Centre for Biotechnology Information (NCBI). The CLUSTAL W v1.82 
program (EMBL) was used to perform the multiple sequence alignment and homology 
studies between rat, mouse and human OKL38. The predicted amino acid sequences were 
analysed using: i) cPfam CDS-Conserved Domain Search (NCBI) for conserved domain 
detection, ii) SignalP (Nielsen and Krogh, 1998) for analysing the present of signal 
peptide, iii) SOSUI (Hirokawa et al., 1998) and Tmpred (Hofmann and Stoffel, 1993) 
program for possible transmembrane region detection and iv) NetNGlyc 1.0 program 
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(Ricort and Binoux, 2004) and NetOGlyc 3.1 program 
(www.cbs.dtu.dk/services/netoglyc) (Julenius et al., 2005) were employed to detect 
possible glycosylation sites. The putative promoter region was analysed using the 
MatInspectorV2.2 (http://transfac.gbf.de/cgi-bin/matSearch/matsearch.pl), CpG Island 
Searcher (http://www.uscnorris.com/cpgislands/cpg.cgi) (Takai and Jones, 2002) and 
Repeat Masker (http://ftp.genome.washington.edu/RM/RepeatMasker.html). 
Statistical Analysis: Chi-square test was used to test the relationship between sex 
and OKL-38 expression in tumours, and between age and OKL-38 expression in tumours. 
Nonparametric trend analysis was used to investigate the correlation between tumour 
stage and OKL-38 expression in tumours. Log-rank test was used for assessing the 
equality of survivor functions. All these analysis were performed by means of STATA 
(StataCorp, 2001. STATA Statistical Software: Release 7.0.  Stata Corporation, College 
Station, TX USA). Statistical significance was established at p<0.05. Survival time of 
those with HCC was calculated from the date of surgery to date of death. The Kaplan-
Meier method was used to estimate survival curves (Altman et al., 2000). The log-rank 
test with one degree of freedom was used to test between OKL38 positive and negative 
staining groups and the hazard ratio and corresponding 95% confident interval calculated. 
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CHAPTER 4: RESULTS 
4.1 Cloning, Sequencing and Characterization of the human 
OKL38 gene 
The established human OKL38 variants sequence and the sequence data from the 
human genomic clone provided a wealth of information for deciphering the genomic 
organization of the human OKL38 gene. Analysis of the entire OKL38 gene will allows 
the elucidation of the relationship between the exon-intron arrangement, protein 
structural domains, and between alternative splicing and translational regulation. 
Furthermore, these works established the foundation for future studies on the promoter(s) 
of OKL38 gene as a prerequisite enabling us to unravel the mechanisms of activation, 
control and regulation of this cancer related gene.  
4.1.1 Screening and sequencing of human OKL38 gene 
In an attempt to isolate the human OKL38 gene, a genomic cosmid library was 
screened employing the 1.6 kb OKL38 cDNA as the probe. Two cosmid clones 
containing human OKL38 gene were isolated during the screening process and their 
identity were determined via Southern blotting. The clone containing a longer insert of 
approximately 35 kb was selected for sequencing.  Direct sequencing of the insert ends in 
the cosmid clones indicated that approximately 100 bp was missing from the 3end of 
OKL38 exon 8. A latter 2.5 kb genomic DNA fragment containing this missing end was 
subsequently cloned using the GenomeWalker kit. The cloning strategy is as shown in 
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figure 4.1A. The sequence information was deposited in Genbank with the accession 
number AF334780.    
Residing in the subclone Bs/X-1.1 (Fig. 4.1A), an approximately 850 bp CCCT 
rich region was identified. About 300 bp within this region could not be sequenced 
through current means. This region was part of intron 2, located 1.2 kb upstream of 
promoter P1 transcriptional start site (Fig. 4.2A). Another interesting region spanning 
~500 bp was identified by Repeat Masker program as simple CA repeats. Careful 
investigation showed that this region contained 4 long repeats with repeat 2 and 3, each 
160 bp, aligned perfectly, while 1 and 4 partly conserved. This region contained 
approximately 70% of cytosine and adenine, and was localized 140 bp upstream of exon 
2 (Fig. 4.2A). The functional significances of these unique regions are unknown at the 
present time. 
4.1.2 Genomic structure of human OKL38 gene 
Sequence comparison between the genomic and cDNA clones allowed the 
deciphering of the exon/intron junctions of the OKL38 gene. Each of the 5-donor and 3-
acceptor splice sites conformed to the consensus sequences with the highly conserved, 
invariable GT/AG dinucleotides present at the immediate exon/intron boundaries 
(Table1). The human OKL38 gene spanned a genomic region of approximately 18 kb and 
contains 8 exons with sizes ranging from 92 bp to 1270 bp (Fig. 4.1B). 
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4.1.3 Discrepancy between the sequenced OKL38 and the Human 
Genome Sequencing Project 
The human OKL38 genomic sequence established in this study was deposited in 
the GenBank before the completion of the Human Sequencing Project (Lander et al., 
2001; Venter et al., 2001). BLAST analysis performed using the present sequence data 
against the published draft human sequence (Genomic contig: NT_024797.13) (NCBI) 
revealed that the OKL38 gene was localized to chromosome 16 (16q23.3). A comparison 
between the sequenced OKL38 gene with the published human genome using ClustalW 
delineated two regions of differences. An approximately 20 bp random deletion in the 
CA repeats region and a 550 bp longer CCCT rich region were observed in the 
sequenced OKL38 gene (Fig. 4.2B). To verify the presence of this longer CCCT rich 
region in our cosmid clone, PCR was performed using a forward primer, V1-F, which 
resides immediately downstream of exon 2 and reverse primer, V1-R, which resides in 
exon 3 (Fig. 4.2B). A PCR product of ~2.5 kb was amplified instead of a 1.95 kb 
fragment, suggesting that the 850 bp CCCT rich region in our clone is not an artefact of 
cloning. The presence of highly repetitive sequences and the discrepancy in sequence 
data may suggest that OKL38 lies in a chromosomal region of instability.    
4.1.4 Identification of OKL38 putative promoters 
Two putative promoters were identified via comparing the 5RACE fragments 
with the cloned OKL38 genomic sequence (Fig. 4.2A). Analyzing the proximal 300 bp 
region of promoter P1 using MatInspector program identified several potential sites for 
the Ikaros factor (IK2), homeodomain factor Nkx-2.5/Csx (NKX25), upstream 
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stimulating factors (USF), myeloid zinc finger protein (MZF1), Sp1 and AP-1, -2 and 4 
(Fig. 4.3A). Using the CpG Island Searcher (Takai and Jones, 2002) (lower limit values 
200 bp for length, 55% for GC content and 0.65 for observed CpG/expected CpG ratio), a 
CpG island of 215 bp located 746 bp upstream of the promoter P1 transcriptional start 
site was identified. No TATA or CAAT boxes were observed upstream of this initiation 
site. However, an alternative core promoter motif termed the initiator (Inr) (Javahery et 
al., 1994), which encompasses the initiation site, was identified (Fig. 4.3B). Interestingly, 
the sequence around this start site, TCAGAGC (position 2 to +5) matched the Inr 
consensus sequences except for the penultimate G, indicating that this core sequence is 
likely responsible for driving transcription from this site. Accordingly, a putative 
downstream promoter element (DPE), ATGGGTG (position +27 to + 33) was identified 
(Javahery et al., 1994) (Fig. 4.3B). Four of the seven nucleotides of this element were 
conserved (i.e. underlined nucleotides).  
On the contrary, none of the basal transcription elements, such as TATA, CAAT, 
Inr or DPE were observed in promoter P2. But several potential sites for IK2, USF, myb 
and, many AP-1 and GATA1 were observed in the 300 bp of the proximal promoter 
region. A CpG island of 278 bp, located approximately 2.5 kb upstream of the putative 
initiation site was identified.    
4.1.5 Establishment of full-length OKL38 variants via 5-Rapid 
Amplification of cDNA Ends and Primer Extension Analysis 
Establishing the variants full-length transcripts is an aspect of the effort to 
decipher the genomic organization of OKL38. The identification and cloning of the 
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OKL38 variants allow further characterization of their functions and regulations. To 
establish the full-length transcripts, 5-Rapid Amplification of cDNA Ends (RACE) was 
performed using poly (A)+ mRNA derived from human kidney tissues. Using GSP1R 
primer residing in exon 6, a PCR fragment of 443 bp, which consists of exon 3, 4 and 5 
was amplified (Fig. 4.4A[ii] & B). The identity of this amplified fragment was verified 
by Southern blot analysis using exon 6 as the probe (Fig. 4.4C). Employing GSP2R 
primer residing in exon 3, a 494 bp fragment was amplified establishing exon 1 (Fig. 
4.4A[iii] & D). This PCR product containing exon 1 was low in copy number (Fig. 4.4D) 
and could only be detected via Southern blot analysis using exon 3 as the probe (Fig. 
4.4E). No fragment containing exon 2 was cloned in the 5 RACE experiment. To 
determine the possibility that the transcriptional start site was located in exon 1 and 3, 
primer extension studies was performed using Pext1 and Pext3 primer residing in the 
respective exons (Fig. 4.4A). The transcription start site preceding exon 3 could be 
observed from RNA derived from liver, kidney and prostate (Fig. 4.5) suggesting the 
presence of a cryptic promoter P1. A minor transcriptional start site at position 10 was 
also detected (Fig. 4.5). However, the transcriptional start site preceding exon 1 was not 
detectable by primer extension studies, suggesting low levels of exon 1 containing 
transcripts.   
4.1.6 Tissue distribution of human OKL38  
Differential expression of OKL38 in rat tissues, but not in the human, has 
previously been shown (Huynh et al., 2001). Human Multiple Tissues Expression (MTE) 
array was adopted to determine the global tissue distribution of human OKL38 (Fig. 
4.6A). The MTE array showed that OKL38 was ubiquitously expressed in all the tissues 
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investigated, with high expression levels detected in the kidney (7:A), skeletal muscle 
(7:B), testis (8:F), liver (9:A), adrenal gland (9:C) and fetal liver (11:D) (Fig. 4.6B). 
Human Multiple Tissues Northern (MTN) blot analysis showed that transcripts of 
approximately 2.0 to 2.4 kb were ubiquitously expressed in all the 15 tissues investigated 
(Fig. 4.7). High expression of these transcripts in liver, kidney and testis confirmed the 
MTE array analysis. Larger putative transcripts ranging from 4.0 to 7.0 kb were also 
observed in the liver (Fig. 4.7A).  
One step RT-PCR was devised to determine the differential expression of human 
OKL38 variants in various tissues. Four RT-PCR products of 443 bp, 373 bp, 533 bp and 
482 bp corresponding to the HuOKL38-1a, -2a, -2b and -2c transcripts, respectively, 
were amplified (Fig. 4.8A-D). A RT-PCR product of 415 bp containing part of exon 7 
and 8, represent total levels of OKL38 transcripts was amplified from kidney, liver and 
ovary (Fig. 4.8E). Figure 4.8A demonstrated that the primers designed for the one step 
RT-PCR were variant-specific and could identify the HuOKL38-1a, -2a and -2b variants. 
Southern blot analysis (Fig. 4.8D) was performed using exon 4 & 5 as probe and 
sequencing verified the identity of the amplified products. The 4 human OKL38 variants 
were expressed in all the three tissues investigated albeit at different levels. HuOKL38-1a 
possesses the highest level of expression as compared to the other 3 variants (i.e. fewer 
PCR cycles required for amplification of the HuOKL38-1a). Highest level of OKL38 
transcripts was detected in the liver as compared to the kidney and ovary (Fig. 4.8B-E), 
which is in-line with the MTN and MTE results. 
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4.1.7 Molecular Cloning of Human OKL38 cDNAs 
Sequence comparison of the 5RACE PCR products derived via employing 
primers GSP1R and GSP2R, and the cloned genomic sequence showed that the first 22 
bp (position +1 to +22 at promoter P1; refer to figure 4.3A) is absent in exon 3 and was 
unique to the HuOKL38-1a variant. To clone the full length HuOKL38-1a, forward 
primer 1F (Table 2) that resided mostly within the 22 bp unique region of the GSP1R 
5RACE fragment and a common reverse primer, 1R (Table 2) were designed for RT-
PCR cloning of the HuOKL38-1a transcript (Fig. 4.9A). Cloning of the HuOKL38-2a 
and 2b transcripts involves usage of forward primer 2F residing in exon 1 instead of 1F 
(Fig. 4.9A). Three PCR products of approximately 1.9, 2.2 and 2.4 kb were cloned and 
five identical clones of each cDNA were sequenced, which allowed establishment of 3 
novel human OKL38 cDNAs of 1930, 2240 and 2400 bp, respectively. The 1.9 kb cDNA 
was annotated as HuOKL38-1a (GenBank Accession No. AY258068), the 2.2 kb cDNA 
as HuOKL38-2a (GenBank Accession No. AY258067) and the 2.4 kb cDNA as 
HuOKL38-2b (GenBank Accession No. AY258066).  
The results from 5 RACE analysis indicate the presence of a transcript containing 
exon 3 (Fig. 4.4A). Expression studies using one-step RT-PCR and Southern blot 
analysis verified that this minor transcript (HuOKL38-2c) contained exon 1, 3, 4, 5 and 6 
(Fig. 4.8). It is likely that this transcript also contains exon 7 and 8 as illustrated in figure 
4.9A. However, due to the low expression of HuOKL38-2c in the liver and kidney RNA 
samples, we have not managed to clone the full-length sequence of this cDNA. The 
cloning of HuOKL38-1a, -2a & -2b variants confirmed the existence of these transcripts.  
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1.1.1 TABLE 2. Sequences of oligonucleotides used for RT-PCR (a), Cloning (b), Sequencing (c), 
Primer extension (d), PCR (e) and 5RACE Primer (f). 
 
Oligonucleotide Sequence 
d Pext1 5  CTGCTGACCCTGACCTTGTTCTAGA 3 
d f Pext3 / GSP2R 5  GGTCAGGGGAACACGGATCACAGAGTCC  3 
f GSP1R / PCR-1R 5  CGTAGAAGGGCATCAAAGAGCAGGG  3 
a b 1F 5  AAGCTTGGATCCCCACAGGGTAATGGGTGT  3 
b 1R 5  GAATTCTGGAAGGCGCAGGGCTGCAGGTCT  3 
b 2F 5  AAGCTTGGCAGGGAGGAAAGTCCACGTCT  3 
a PCR-1R  5  CGTAGAAGGGCATCAAAGAGCAGGG  3 
a PCR-2F 5  GGGAAGTGGAGACTGAGAGGCTGCTGC  3 
b 477-F 5  CACCATGAGCTCCTCCAGAAAGGACCA  3 
b 477-eGFP-R 5  CTCGCCCTTGCTCACCATGGGTGGCTTCCTGGTCTC  3 
b eGFP-F 5  ATGGTGAGCAAGGGCGAG  3 
b eGFP-R 5  TTACTTGTACAGCTCGTCCA  3 
c Seq1R 5  CTGGTCAGGAAGCCGCTCACCTGGAAGA  3 
c Seq2R 5  CAGTCTTCCTTGAAGCACAGCAGCTGGT  3 
c Seq3R 5  GATGGCGTGCTCCTTCCGGTGCTTCC  3 
c Seq4F / GW-F 5  GAGATGACCACATCCCTGCTGGATGC  3 
c Seq5F 5  GTGTTCAACCAGCTGCCCAAGATGC  3 
c P1F 5  CTGAGGAAGAGGGAGGCAAGAGACAGAG  3 
c P1R 5  GCTGATATGGGGAACTGTGGGGCGAGAC  3 
e V-1F 5  AGGCATCACCTCAGGCACAA  3 
e V-1R 5  CTGACAGGCAGTGGTGCAGGA  3 
b 1aORF-F 5- AAGCTTGGATCCCCACAGGGTAATGGGTGT -3 
b ORF-R 5- GAATTCTTAGGGTGGCTTCCTGGTCTCCTTCC -3 
b 2bORF-F 5- AAGCTTCACCGTGGGATGGGGAA -3 
b 1aD1-F 5- AAGCTTCTGTGATCCGTGTTCCC -3 
b 1aD2-F 5- AAGCTTGGCCGGGCTCACT -3 
b 2aD1-F 5- AAGCTTTGGAGGAAGGCCAGG -3 
b 2aD2-F 5- AAGCTTCTCAAGCCCCAGCCTT -3 
b 2aD3-F 5- AAGCTTCAAAACCACTGGGAAGC -3 
b 2aD4-F 5- AAGCTTGGAGACTGAGAGGCTGCT -3 
b UTR-R 5- GAATTCATGGCTGGTGGGGGGCTT -3 
b E4-F 5- AGCTTAGGTCCGCTGCCAGCCCCAAGCCCCCCACCAGCCATG -3 
b E4-R 5- AATTCATGGCTGGTGGGGGGCTTGGGGCTGGCAGCGGACCTA -3 
a E7TF 5- GTCAAGGACTGGATGCAGAAGA -3 
a E8TR 5- CAATGATGAGGACAGGGTCTGA -3 
c E81R 5- TCTTCCAGGTGAGCGGCTTCCTGACCAG -3 
c E82R 5- ACCAGCTGCTGTGCTTCAAGGAAGACTG -3 
c E81F 5- GTGTTCAACCAGCTGCCCAAGATGC -3 
c E61R 5- CCCTGCTCTTTGATGCCCTTCTACG -3 
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4.1.8 Sequence analysis of Human OKL38 variants 
Detailed sequence analysis of the human OKL38 variants would reveal useful 
information on the functions and regulations of the gene. The results from sequence 
analysis indicated that differential promoter usage and alternative splicing at the 5 region 
of OKL38 gene were responsible for the variants existence. HuOKL38-1a transcript was 
derived from the usage of promoter P1, while HuOKL38-2a, -2b and -2c expression 
might be regulated via promoter P2. The HuOKL38-2a, -2b and -2c were derived by 
alternative splicing of exon 2 and 3, exon 3 and exon 2, respectively (Fig. 4.9A). The 
HuOKL38-1a and -2a variants harboured an ORF of 1431 base pairs. The conceptual 
translation of these cDNAs predicted a protein of 477 amino acids, with a calculated 
molecular mass of 52 kDa (Fig. 4.9B) and a predicted P. I. of 6.6.  Two other protein 
isoforms with a molecular weight of 61 and 59 kDa were also predicted from HuOKL38-
2b and -2c, respectively (Fig. 4.9B). In vitro Transcription and Translation study 
employing the cloned HuOKL38-1a, -2a, and -2b resulted in the synthesis of two proteins 
of approximately 52 and 61 kDa (Fig. 4.10A) and their identity was confirmed via 
Western blot analysis using anti-human OKL38 antibodies (Fig. 4.10B). The previously 
cloned OKL38 cDNA (GenBank Accession No. AF191740) showed the expression of a 
38 kDa protein. Western blot analysis also detected low levels of the 38 kDa protein from 
these larger cDNA constructs suggesting that translation from an internal translation start 
codon (AUG) might exist (Fig. 4.10B). The predicted internal inframe start codon (AUG) 
and the molecular weight of the putative proteins in HuOKL38-1a were highlighted in 
figure 4.11. None of the predicted inframe ORF contains the Kozaks consensus sequence
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(Fig. 4.11B). An out of frame ORF (position 296-472 nt) was also identified within the 
52 kDa ORF, which may play a role in internal translation initiation (Fig. 4.11A). 
The human OKL38 cDNA variants derived through differential promoters usage 
and alternative splicing contained 5UTRs of varying length (Fig. 4.12A). The 5UTR of 
HuOKL38-1a is 162 bp in length, while the 5UTRs of HuOKL38-2a and -2b are 472 bp 
and 383 bp in length, respectively. Small uORF of 10 amino acids was detected in the 
5UTR of HuOKL38-1a transcripts, while two uORFs of 21 and 30 amino acids were 
identified in the 5UTRs of the HuOKL38-2a transcripts (Fig. 4.12A). Similarly, the 21 
amino acids uORF was also present in the HuOKL38-2b transcripts, which resided in 
exon 1. The lower translation efficiency of HuOKL38-2a and -2b observed in the in vitro 
Transcription and Translation results (Fig. 4.10) suggest that these uORFs may play a 
role in translational suppression.   
Similar to the previously cloned human OKL38 protein, no putative signal peptide 
was found in all three human OKL38 protein isoforms using the publicly available 
SignalP program (Nielsen and Krogh, 1998) and no potential glycosylation site was 
detected suggesting a protein of cytoplasmic distribution. Computational analysis of the 
predicted amino acid sequence using Pfam CDS-Conserved Domain Search (NCBI) 
detected two putative domains belonging to that of the pyridine nucleotide-disulphide 
oxidoreductase (Pyr_redox) and TrkA in all three human OKL38 isoforms (Fig. 4.12B). 
The TrkA domain (amino acid position 100-301) in OKL38 protein is 40% identical to 
the consensus sequences and is encoded by exon 6-8. The Pyr_redox domain (amino acid 
position 239-446) in OKL38 protein is 61.8 % identical to the consensus sequences and is 
  RESULTS 
________________________________________________________________________ 
 82
  RESULTS 
________________________________________________________________________ 
 83
encoded by exon 8. The two domains overlaps each other by about 60 amino acids as 
shown in Figure 4.12B.  
4.1.9 Over-expression of OKL38 is lethal to A498 and Chang Liver 
cells  
Previous study demonstrated the growth inhibitory function of OKL38 suggesting 
its tumour suppressor role in breast cancer (Huynh et al., 2001). To further characterize 
the function of the full-length OKL38 protein (52 kDa), an OKL38-eGFP-pcDNA3.0 
construct with a fused reporter gene eGFP to the C-terminal of OKL38 protein, was 
generated. Preliminary transfection studies showed that OKL38-eGFP recombinant 
protein formed aggregates in A498 kidney cancer cells as early as 24 hours post-
transfection (Fig. 4.13B). None of the cells expressing the recombinant protein survived 
96 hours post-transfection as compared to the eGFP positive control cells. The results 
showed that over-expression of OKL38 protein is lethal to A498 cells.  
Seeming from the above observations, Chang liver cells were transiently 
transfected with the earlier constructs OKL38-eGFP-pcDNA3.0 and eGFP-pcDNA3.0 
positive control plasmid (Fig. 4.14A-D). Similar to the observations in A489 kidney 
cancer cells, green aggregates were observed in the Chang liver cells 24 hours post-
transfection (Fig. 4.14B). Rounding up of the OKL38-eGFP-transfected cells was 
observed and cell death was evident 48 hours post-transfection (Fig. 4.14C & D). After 5 
days of culture, virtually no OKL38-eGFP-expressed cells were detected as compared to the 
controls.  
To exclude the possibility that cell death was a consequence of misfolding of the 
large OKL38-eGFP recombinant protein, OKL38 without eGFP was constructed and 
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transfected as described above. Immunohistochemical staining using OKL38 antibody 
showed that Chang Liver cells over-expressing the FL-ORF rounded up and were non-
viable (Fig. 4.14E & F). Western Blot analysis showed that the transiently transfected 
Chang liver cells expressed a protein of approximately 52 kDa (Fig. 4.14G). However, 
viable cells selected under the presence of G418 had lost OKL38 expression, suggesting 
that over-expression of OKL38 is lethal to both A498 and Chang Liver cells (Fig. 4.13 & 
4.14). 
4.2 Cloning and Characterization of rat OKL38 gene 
Animal models are valuable tools to researchers as they provide a platform for 
testing efficacy of drugs and in vivo characterization of novel genes. In order to develop a 
rat model for further characterization of OKL38s role in growth, differentiation and 
tumourigenesis, the rat OKL38 gene was isolated and characterized. Deciphering the 
genomic structure and cloning of the rat OKL38 variants provide the foundation for 
future studies.   
4.2.1 Genomic structure of Rat OKL38 gene 
In silico data mining is widely used to harness the vast amount of information 
freely available in the Internet, especially with the completion of the human and other 
mammalian genome sequencing projects. Employing the NCBI BLAST algorithm, the 
sequence of the three cloned rat OKL38 cDNAs in this study were used to search against 
the Genbank sequence database. The rat OKL38 gene was mapped onto the rat 
chromosome 19q12 (WGS supercontig; NW_043217.1). Using the sequence information, 
the genomic structure of the rat OKL38 gene was deduced (Fig. 4.15), and the 
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exon/intron boundaries were established. Each of the 5-donor and 3-acceptor splice 
sites conformed to the consensus sequences with the highly conserved, invariable GT/AG 
dinucleotides present at the immediate exon/intron boundaries (Table 3). The rat OKL38 
gene spanned a genomic region of approximately 15 kb and comprised of 8 exons with 
sizes ranging from 92 bp to 1314 bp (Table 3). 
The 5RACE results and cloning of the rat OKL38 mRNA isoforms suggested 
that differential promoter usage and alternative splicing at the 5 region of OKL38 gene 
might be responsible for the presence of the variants. Two putative promoters were also 
identified via 5RACE analysis and sequence comparison in this study (Fig. 4.15). The 
RtOKL38-2.3 cDNA contained all the 8 exons, while the RtOKL38-2.3A cDNA was 
derived by alternative splicing of exon 3 (Fig. 4.15). Both the RtOKL38-2.3 and -2.3A 
transcripts were likely arrived as a result of upstream promoter (promoter P2) usage, 
while the cryptic promoter (promoter P1) in intron 2 might give rise to the RtOKL38-2.0 
transcript, which only consists of exon 3 to 8 (Fig. 4.15). The results indicate that 
activities of promoter P2 are tissue-specific as the RtOKL38-2.3 and 2.3A variants 
could only be detected in the kidney (Fig. 4.16B & 4.19B). 
4.2.2 Isolation of rat OKL38 cDNA 
The cloning of human OKL38 cDNA (Accession No. AF191740) was previously 
reported to be cloned from a human ovarian cDNA library (Huynh et al., 2001). OKL38 
transcripts were detected at high levels in the ovary, kidney and liver of rat (Huynh et al., 
2001) and human as shown in this study. To facilitate the development of a rat model, it 
is necessary to isolate the rat OKL38 cDNA. The human OKL38 cDNA was used as a 
probe to screen rat liver cDNA library. Four positive plaques were isolated and further 
  RESULTS 
________________________________________________________________________ 
 90
  RESULTS 
________________________________________________________________________ 
 91
characterized with the longest insert of 1093 bp. Blast search with the non-redundant 
nucleotide database (GenBank) showed that the nucleotide sequence of the isolated rat 
OKL38 cDNA was 85% and 90% identical to the previously published human OKL38 
cDNA (Huynh et al., 2001) and the mouse counterpart IMAGE:37844 (GenBank 
Accession No. BC022135), respectively. 
4.2.3 Establishment of full-length cDNA of rat OKL38 variants 
The Northern blot results showed that the rat OKL38 transcript is approximately 2 
kb in size and the longest cDNA isolated via cDNA library screening was 1093 bp. To 
establish the full-length transcripts, 5RACE was performed using poly (A)+ mRNA 
derived from both rat liver and kidney tissues. Two major fragments of approximately 1.1 
and 1.4 kb were obtained after secondary PCR amplification (Fig. 4.16B). The 1.1 kb 
fragment was detected in both liver and kidney, whereas the 1.4 kb fragment was only 
found in the kidney (Fig. 4.16B). Sequence alignment analysis using ClustalW program 
(EMBL) revealed that the 1.1 kb fragment from the liver was identical to that cloned 
from the kidney. The sequence of the 1.1 kb fragment aligned perfectly from the 3 end 
with the 1.4 kb fragment except for the first 43 nucleotides, which were found uniquely 
in the 5 end of the 1.1 kb fragment (Fig. 4.16A). 
4.2.4 Tissue distribution of rat OKL38 
To determine the tissue distribution of rat OKL38 transcripts, Northern blot 
analysis was performed using 5 µg of poly (A)+ mRNA isolated from various rat tissues 
and hybridised with radio-labelled rat OKL38 probe. Transcripts of approximately 2.0 
and 2.3 kb were detected in the kidney, while the 2.0 kb transcript was ubiquitously 
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expressed in liver, ovary, mammary gland and uterus (Fig. 4.17A). The RtOKL38-2.3 
and -2.2 variants were differentially expressed in the kidney, which were detected by 
variants specific probe (Fig. 4.17B). Larger putative transcripts ranging from 4.0 to 9.0 
kb were observed in both the liver and kidney (Fig. 4.17A). The overall expression 
pattern of rat OKL38 mRNA coincided with earlier published reports (Huynh et al., 
2001). 
To facilitate the differential tissues expression studies of rat OKL38 variants, 
variant-specific primers were designed and verified via PCR (Fig. 4.18). The distribution 
of rat OKL38 variants in various rat tissues was determined via One Step RT-PCR using 
variant-specific primers illustrated in figure 4.18A. The specificity of the designed 
primers for RT-PCR detection of rat OKL38 variants was verified via PCR (Fig. 4.18B). 
Three RT-PCR products of 432 bp, 791 bp and 690 bp were amplified and these 
corresponded to the RtOKL38-2.0, -2.3 and -2.3A transcripts, respectively (Fig. 4.19A-
C). The RtOKL38-2.0 transcript was detected at high levels in the liver, kidney and 
ovary. The observation was in agreement with the earlier results from Northern blot 
analysis (Fig. 4.17A). Low levels of RtOKL38-2.0 transcript were detected in mammary 
gland and uterus (Fig. 4.19A). The RtOKL38-2.3 transcript was specifically detected in 
the kidney (Fig. 4.19B & C) and its identity was verified via direct sequencing and 
Southern blot analysis (Fig. 4.19C). Southern blot analysis revealed very low level of the 
RtOKL38-2.3 cDNA in the liver with no detectable expression in the ovary, mammary 
gland and uterus (Fig. 4.19B & C). A smaller fragment of 690 bp was repeatedly 
amplified in RNA sample derived from kidney (Fig. 4.19B & C) and this fragment 
probably belongs to the existing OKL38 cDNAs or another novel variant. To investigate 
  RESULTS 
________________________________________________________________________ 
 93
  RESULTS 
________________________________________________________________________ 
 94
  RESULTS 
________________________________________________________________________ 
 95
  RESULTS 
________________________________________________________________________ 
 96
this possibility, the 690 bp fragment was cloned and sequence analysis found that it 
belonged to an alternatively spliced form of the RtOKL38-2.3 variant, which was 
annotated as RtOKL38-2.3A (Fig. 4.18A).   
4.2.5 Cloning of rat OKL38 variants  
Using RT-PCR amplification, the full-length cDNA belonging to the 1.1 kb 
5RACE fragment was cloned using forward primer FL-2.0F (Table 4) residing within 
the unique 43 bp region of the 1.1 kb 5RACE fragment and a reverse primer, FL-2.0R 
(Table 4) (Fig. 4.20). The cloning of the cDNA belonging to the 1.4 kb RACE fragment 
was amplified using forward primer FL-2.3F (Table 4) residing in the 5 end of the 1.4 kb 
fragment together with FL-2.0R primer (Fig. 4.20). The same set of primers was also 
used for the cloning of RtOKL38-2.3A variant. Since the RtOKL38-2.0, -2.3 and -2.3A 
transcripts were abundant in the kidney, these transcripts were subsequently cloned from 
the kidney. Three PCR products of 2.0, 2.2 and 2.3 kb were cloned and five identical 
clones from each were sequenced, which enabled the establishment of three rat OKL38 
cDNAs of 2003 bp, 2256 bp and 2355 bp, respectively. The sizes of these three cDNAs 
were in agreement with the transcript sizes observed in Northern blot analysis (Fig. 
4.17A & B).  These three rat OKL38 cDNAs of sizes 2.0 kb, 2.2 kb and 2.3 kb were 
collectively annotated as RtOKL38-2.0 (GenBank Accession No. AY081218), 
RtOKL38-2.3A (GenBank Accession No. AF549442) and RtOKL38-2.3 (GenBank 
Accession No. AF549441), respectively. Full-length cloning of the three rat OKL38 
variants and subsequent sequencing confirmed their existence.  
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4.2.6 Sequence analysis of rat OKL38 variants 
The comparison of primary amino acid sequences from human, rat and mouse 
were illustrated in figure 4.21 using ClustalW (EMBL). Multiple sequence alignment 
study showed that the rat and mouse OKL38 (GenBank Accession No. BC022135) 
shared a high identity of 91% and 93% at the nucleotide and amino acid levels, 
respectively (Fig. 4.21). The identity between the rat and human OKL38 was only 80% at 
the nucleotide and 85% at the amino acid levels, respectively (Fig. 4.21).  
The RtOKL38-2.0 cDNA harboured an ORF of 1434 base pairs with a conceptual 
translated protein of 478 amino acids, having a calculated molecular mass of 52 kDa and 
a predicted P. I. of 6.83. In vitro Transcription and Translation studies using the 
RtOKL38-2.0, -2.3 and -2.3A cDNAs resulted in the synthesis of an approximately 52 
kDa protein (Fig. 4.22A) and its identity was confirmed by Western blot analysis using 
anti-OKL38 antibodies (Fig. 4.22B). 
Computational analysis of the predicted amino acid sequence using Pfam CDS-
Conserved Domain Search (NCBI) detected two putative domains belonging to that of 
the pyridine nucleotide-disulphide oxidoreductase (Pyr_redox) and TrkA (Fig. 4.12B & 
4.21). The Pyr_redox domain was also present in glutathione reductase, thioredoxin 
reductase, AIF, AIFL and PRG3/AMID (Fig. 4.23). The glutathione reductase and 
thioredoxin reductase carry an additional Dimerization domain, whereas the AIFL 
contain an additional Rieske domain (Fig. 4.23). Similar to that observed in human, the 
rat OKL38 Pyr_redox domain is resided in exon 8, while the TrkA domain is encoded by 
exon 6-8. The hydrophobicity average of rat OKL38 was 0.200209, and was predicted to 
be a cytosolic protein using the SOSUI (Hirokawa et al., 1998) and Tmpred (Hofmann 
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and Stoffel, 1993) programs. However, two putative N-linked and O-linked glycosylation 
sites at Asparagine-283 and Threonine-285, respectively, were identified using the 
NetOGlyc 3.1 program (Julenius et al., 2005) (Fig. 4.21). These two glycosylation sites 
were not conserved in the human OKL38 protein (Fig. 4.21).  
Sequence alignment studies of RtOKL38-2.0, -2.3 and -2.3A cDNAs showed that 
the three variants shared the same 3end and the only differences were observed at the 5 
end. Inspecting the 5UTR of the three RtOKL38 cDNAs revealed the presence of an in-
frame stop codon (UGA) 18 bp upstream of the predicted translational start site (AUG). 
Despite the differences in the 5 end, the RtOKL38-2.0, -2.3 and -2.3A variants possess 
identical ORF. In-frame small upstream ORFs (uORFs) that encodes for 66 and 33 amino 
acids were detected in the 5UTR of the RtOKL38-2.3 and -2.3A variants, respectively 
(Fig. 4.12A). Two other uORFs of 12 and 46 amino acids were also detected in the 
5UTRs of these two rat OKL38 variants. A small uORF of 21 amino acids was identified 
within the 5UTR of RtOKL38-2.0 (Fig. 4.12A). These observations suggest the possible 
involvement of uORF and uAUG in translation regulation. 
4.2.7 Functional expression of rat OKL38 protein  
In this study, the cellular localization and function(s) of rat OKL38 protein was 
investigated. RtOKL38-eGFP-pcDNA3.0 construct, which fused the reporter gene eGFP 
to the C-terminal of full-length rat OKL38 protein, was constructed. Preliminary 
transfection studies showed that RtOKL38-eGFP fusion protein was localized to the 
cytosol, resulting in protein aggregates in BRL cells as early as 24 hours post-transfection 
(Fig. 4.24A). Cells expressing the fusion protein gradually rounded up and almost all the 
RtOKL38-eGFP expressing cells disintegrated 120 hours post-transfection. On the other 
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hand, cell growth was observed in the cells transfected with the control eGFP or eGFP-
antisense-RtOKL38 constructs. The presence of the fusion protein (RtOKL38-eGFP) was 
verified via Western blot analysis performed on the transfected cell using the anti rat 
OKL38 antibody (Fig. 4.24C). These observations indicate that over-expression of 
OKL38 protein was probably lethal to BRL cells.   
4.3 Pregnancy and human chorionic gonadotropin (hCG) 
regulate OKL38 expressions 
The ability of early pregnancy and hCG treatment to protect the breast against 
mammary carcinogenesis has been well documented (Russo et al., 1990b; Russo et al., 
1990a; Russo et al., 1991). Previous studies have demonstrated that OKL38 is 
differentially regulated in the rat mammary gland throughout the course of pregnancy 
(Huynh et al., 2001). Since CG production by placenta increases during pregnancy, the 
effects of hCG on the regulation of OKL38 in rat mammary gland and ovary were 
investigated.   
4.3.1 Rat OKL38 protein is up regulated during pregnancy 
OKL38 transcripts were up-regulated in the rat mammary gland during pregnancy 
(Huynh et al., 2001). In the present study, the effect of pregnancy on rat OKL38 protein 
in the mammary gland was determined. Western blot analysis showed that OKL38 
protein was highly expressed in the mammary glands of the pregnant and lactating rats, 
while the protein was barely detectable in the non-pregnant mammary glands (Fig. 
4.25A). The level of OKL38 protein expression returned to basal levels during 
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involution. Several OKL38 protein isoforms were evident in the rat mammary tissue 
suggesting the probable presence of OKL38 variants.    
4.3.2 Human chorionic gonadotropin induce the expression of rat 
OKL38 
The onset and advancement of pregnancy up-regulated OKL38 expression in the 
mammary gland, it was therefore important to determine whether pregnancy hormones 
such as CG was able to up-regulate OKL38. Total RNA derived from ovary and 
mammary gland of hCG-treated rats was used for Northern blot analysis. OKL38 
transcript was significantly increased in a dose-dependent manner by hCG treatment, 
while low levels of transcript was observed in the mammary gland (Fig. 4.26A) and 
ovary (Fig. 4.26C) of vehicle-treated rats. In the ovary, hCG also induced the expression 
of OKL38 protein (Fig. 4.27A). Interestingly, the 52 kDa OKL38 isoform was only 
detected in the ovary suggesting the tissue specific nature of the various isoforms (Fig. 
4.27A). Unlike the ovary and the mammary gland, OKL38 expression in the liver and 
kidney was not influenced by hCG (data not shown). 
In situ hybridization analysis was performed to determine the cell specific 
expression of OKL38 in both mammary gland and ovary following hCG treatment. Low 
levels of OKL38 transcript expression in undifferentiated mammary epithelial cells of 
control rats had previously been demonstrated (Huynh et al., 2001). In this study, cryo-
sections derived from mammary tissues and ovaries of controls and hCG-treated rats (20 
IU/day) were hybridised with a sense and anti-sense OKL38 RNA dioxigenin-labeled 
probes. Intense signal was observed in the differentiated secretory epithelial cells of the 
mammary gland (Fig. 4.28B). In contrast, little or no signal was detected in the 
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undifferentiated control mammary gland, blood vessels and connective tissues (Fig. 
4.28A & B, indicated by arrow). Low OKL38 signal was detected in the granulosa cells 
of the ovary in the control vehicle-treated rats (Fig. 4.28D). Expression of OKL38 was 
greatly increased in the large corpora lutea and granulosa cells in the follicles of hCG-
treated rats (Fig. 4.28E). No signal was detected in the connective tissues of the ovary 
(Fig. 4.28E, indicated by arrow). The control sense OKL38 RNA probe produces 
background signals in the mammary tissue (Fig. 4.28C) and ovary (Fig. 4.28F). 
4.4 OKL38 and Cancer 
Genes that are differentially expressed or lost in cancers are of great interest to 
scientists. The expression profiles of these genes are closely related to their functions (i.e. 
oncogenes or tumour-suppressor genes) and may serve as useful biomarkers for diagnosis 
and/or prognosis of cancers. These cancer-related genes usually play important roles in 
cell cycle, angiogenesis, apoptosis, proliferation, growth and differentiation. OKL38 has 
been implicated in regulating cell growth and differentiation, and tumourigenesis (Huynh 
et al., 2001). Thus, the distribution of human OKL38 variants in various human normal/ 
tumour tissues and cancerous cell lines were of particular interest. 
4.4.1 Expression of human OKL38 variants in Kidney, Liver and 
ovarian Tissues and cell lines 
A preliminary study of OKL38 expression in various tumours and cancer cell 
lines was performed. The expression of OKL38 variants in tumour and adjacent benign 
tissue, and cancer cell lines were determined via One Step RT-PCR using variant-specific 
primers (Fig 4.29). Southern blot analysis (Fig. 4.29C) was performed using exon 4 & 5 
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as probe and sequencing verified the identity of the amplified products. In general the 
normal kidney, liver and ovarian tissues seemed to express similar level of OKL38 
transcripts as compared to the adjacent tumour tissues. All the cancer cell lines showed 
lower expression of OKL38 transcripts compared to their corresponding normal tissue, 
except for the A498 kidney cancer cell line (Fig. 4.29). However, more paired tissue 
samples and cell lines are needed in order to determine the significant differences in the 
expression level of each variant in normal and cancerous tissues. 
4.4.2 Loss of OKL38 expression in Kidney Cancer 
Cancer Profiling Array (CPA) was used to determine the expression of OKL38 
mRNA transcripts in paired normal/ tumour kidney. The CPA blot was probed with a 
pan-OKL38 variants probe (Fig. 4.30A). The results showed that 70% (14/20) of the 
kidney tumours expressed lower levels of OKL38 transcripts as compared to adjacent 
normal tissues (Fig. 4.30B).   
The OKL38 mRNA transcripts were generally down-regulated in the kidney 
tumours, which led to investigating the possibility of reduction of OKL38 protein in the 
tumours. Western blot analysis was performed using rabbit anti-human OKL38 antibody 
on 9 paired normal/ tumour kidney tissues (Fig. 4.31A). The results showed that OKL38 
protein was undetected in 78% (7/9) of the tumour kidney tissues as compared to their 
adjacent normal tissues. The endogenous 61 kDa, 52 kDa and 38 kDa isoforms of human 
OKL38 protein were also detected by Western blot analysis (Fig. 4.31A), which is in 
agreement with the earlier in vitro Transcription and Translation results (Fig. 4.10). Low 
levels of OKL38 protein was detected in the A498 kidney cancer cell line, contrary to the 
RT-PCR results in which high amounts of OKL38 transcripts were detected (Fig. 4.29). 
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The 61 kDa and 38 kDa proteins were differentially down-regulated in all the kidney 
tumour tissues (Fig. 4.31A).  
Immunohistochemical analysis was performed on 22 paired normal/ tumour 
kidney tissues using the above-mentioned OKL38 antibodies (Fig. 4.32). OKL38 protein 
was undetected in 64% (14/22) of the kidney tumours examined, which supported the 
observation in Western blot analysis. All normal kidney epithelial cells were positive for 
OKL38 protein, except the Bowmans capsules (arrow) and the stroma (Fig. 4.32A), 
while no immunostaining of the tumour cell were observed (Fig. 4.32B). The OKL38 
antibody preadsorbed with 50X excess antigen peptide showed negative signal in 
Western blot analysis (Fig. 4.31C) and Immunohistochemical analysis (4.32C&D) 
demonstrating the specificity of anti-human OKL38 antibody used in this study.  
4.4.3 Loss of OKL38 protein in Liver Cancer of higher stages 
The high levels of OKL38 transcripts in liver, low levels in breast cancer cell lines 
(Huynh et al., 2001), and loss of OKL38 protein in kidney tumour and cell line prompted 
the investigation of its expression in hepatocellular carcinoma (HCC). The abundance of 
OKL38 gene was investigated in 28-paired of adjacent benign liver (ABL) tissue and HCC, 
and 4 liver cancer cell lines (HepG2, Hep3B, Chang Liver and PLC/PRF5) by Western 
blotting (Fig. 4.33A). The 38 kDa OKL38 protein isoform was readily detected in the 
human liver, whereas the other isoforms (i.e. 52 and 61 kDa) were only detectable upon 
extended exposure. Loss of OKL38 protein was observed in 42.8% (12 of 28) of the HCCs 
and in all liver cancer cell lines examined. Low levels of OKL38 were also detected in 
21.4% (6 of 28) of the cancerous tissues compared to ABL tissues (Fig. 4.33A).  
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One step RT-PCR was performed to determine the abundance of total OKL38 
transcripts and its individual variants in 19 of the 28 patient paired-HCC samples. The 
results showed that OKL38 transcripts were down-regulated or lost in 37 % (7 of 19) and 
over-expressed in 16% (3 of 19) of the HCC samples investigated (Fig. 4.33C-E). No 
significant differences in the levels of OKL38 transcripts were detected in the rest (9 of 
19) of the HCC samples (Fig. 4.33C-E). Relatively high levels of OKL38 transcripts were 
detected in the liver cancer cell lines, especially in the HepG2 cells, while no protein was 
observed (Fig. 4.33). 
To identify the cell-type responsible for the loss of OKL38 and verify its potential 
use as biomarker, a total of 92 HCC and their ABL tissues were examined by 
immunohistochemistry. Figure 4.34A shows that intense staining was observed in the 
cytoplasm of adjacent benign hepatocytes. Hepatocytes within cirrhotic nodules were 
stained with OKL38 antibody. Approximately 41.3% (38 of 92) of HCCs examined were 
negative for OKL38 protein (Table 5A). Weak and patchy staining for OKL38 as shown 
in figure 4.34B, was observed in 39.1% (36 of 92) of HCC compared with ABL tissue 
(Table 5A). Bile duct epithelial cells and blood vessels were uniformly negative, as were 
the fibrovascular stroma within cirrhotic livers (Fig. 4.34B-D). Similar results as 
observed in the kidney cancer, OKL38 protein is also lost in HCC. Intense cytoplasmic 
staining was found in dysplasic or benign hepatocytes. 
Table 5B summarized the tumour stage and the immunohistochemical analysis of 
OKL38 in human HCC. Loss or weak, patchy expression of OKL38 was found to occur 
at higher frequencies in stage 3 and 4 tumours, while most of stage 1 and part of stage 2 
tumours still retained high levels of OKL38 expression. Significant relationship was found 
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Table 5: Frequency of distributions of Clinico-pathological factors (92 patients) 
 
Samples  OKL-38 Staining Distribution of OKL-38 expression 
HCC  Negative 
 Weak and patchy 
 Average 





Benign Liver  Positive, very strong  
 diffused 
92/92 (100%) 




OKL 38 Staining Stages 
 I II III IV 
Negative 0 20/50 8/22 10/12 
Weak and patchy positive 2/8 20/50 14/22 2/12 
Strong positive 6/8 10/50 0 0 
 
Variables n % no of deaths (%) 
Sex       
Male 75 81.5 17/75 (26.7) 
Female 17 18.5 7/17 (41.1%) 
Age (year)       
<60 37 40.2 6/37 (16.2%) 
>60 55 59.8 18/55 (32.7%) 
Tumour stage       
I 8 8.7 0 
II 50 54.3 14/50 (28%) 
III 22 23.9 6/22 (27.3%) 
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between stages of HCC and the loss of OKL38 expression (Non-parametric trend 
analysis: Chi2(1) = 8.1796, P = 0.0042). Comparison of the survival between those with 
positive and negative OKL38 staining suggested no correlation between OKL38 
expression and overall survival in curative resection HCC (Log-rank test: Chi2(5) = 3.92, P 
= 0.5613). Age (Chi2(5) = 1.9273, P = 0.859) and sex (Chi2(5) = 6.2945, P = 0.279) of the 
patients appear not to be significantly correlated to OKL38 expression (Table 5C).  
4.5 Post-transcriptional regulation of OKL38 protein translation 
Understanding the regulations of any genes is as crucial as characterization of its 
functions. This study and previous works (Huynh et al., 2001) have highlighted the 
significance of OKL38 in tumourigenesis rendering unveiling the mechanisms of OKL38 
regulations imperative. Since OKL38 is differentially lost in kidney and liver cancers, 
deciphering the regulatory mechanisms of this gene is of particular interest.  
4.5.1 The ORF of OKL38 is intact in the liver cancer cell line and HCC  
Approximately half of the paired-HCC samples showed no significant difference 
in the levels of OKL38 transcripts expression between the ABL tissues and HCC (Fig. 
4.33). Comparing the expression profile between the OKL38 protein and its transcripts, 
42 % (8 of 19) of the paired liver normal/tumours OKL38 transcripts levels did not 
correlate with the protein expression (Fig. 4.33). OKL38 transcripts were detected in all 
four cancer cell lines but the protein was absent (Fig. 4.33). Similar phenomenon was 
observed in the A498 kidney cancer cell (Fig. 4.29 & 4.31). Based on the above 
observations, we postulated that the discrepancy between mRNA and protein levels could 
be due to (1) mutations within the coding region leading to frame shift or change of 
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amino acid sequence, which resulted in loss of protein expression or protein produced not 
detectable by anti-OKL38 antibody; (2) the UTRs may be involved in the translation 
regulation of OKL38 protein expression. 
To examine the first possibility, HuOKL38-1a variants which consist of exon 3 to 
8 was amplified by RT-PCR from 4 liver cancer cell lines and 5 paired HCC tissues that 
had low or undetectable level of OKL38 protein but high levels of OKL38 transcripts. 
Direct sequencing was performed using internal primers (Table 2) and the results were 
summarized in Figure 4.35. Sequence analysis showed that the 52 kDa ORF of OKL38 
was intact in all 4 liver cancer cell lines and in 5 paired HCC and their ABL tissues. 
Three sites of silent mutation were detected in the ORF; AG at position 1017 bp in 
both Hep3B and PLC/PRF5 cells, CA at position 1245 bp in HepG2 cells and a 
probable single allele mutation (i.e. double peak detected in the sequencing results-C/G) 
detected in patient 10 tumour sample at position 984 bp. A cytosine was deleted at 
position 1605 bp in the Chang liver cell, and a TC mutation at position 1801 bp in the 
3UTR of OKL38 gene from both the PLC/PRF5 and Chang Liver cell lines. The 
positions described above are with reference to published HuOKL38-1a variant. The 
results suggest that frame-shift mutation may not be the culprit for down-regulation or 
silencing the expression of OKL38 protein in HCC. 
4.5.2 5UTR of OKL38 variants suppress the translation of its mRNAs  
The earlier results from mutation studies indicated that the alternative hypothesis 
might be true, where the UTRs might be involved in translational down-regulation of 
OKL38 protein in the liver cancer cell lines and HCC samples. The roles of UTRs in 
translational regulation of OKL38 mRNAs were investigated. HuOKL38-1a and -2a 
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variants share the same ORF that encodes a 52 kDa protein, while the HuOKL38-2b 
variant translates into a larger protein of 62 kDa. The three OKL38 variants differ in the 
5UTRs but share the same 3UTR. Using OKL38 protein as a reporter gene, constructs 
with and without the different UTRs were generated by PCR from these variants and 
cloned into the mammalian expression vector, pcDNA3.0 (Fig. 4.36). In vitro 
Transcription and Translation was performed for all the cloned constructs and differential 
expression of S35-radio-labeled OKL38 protein was shown in Figure 4.37A. The same 
blot was probed with anti-human OKL38 antibodies to verify its identity (Fig. 4.37B). 
The same set of constructs as shown in figure 4.36 were transfected into Chang Liver 
cells to further verify the In vitro Transcription and Translation results (Fig. 4.37C).  
As shown in Figure 4.37A-C, all the constructs that contained the 5UTRs (i.e. 
1aFL, 2aFL, 1a5UTR, 2a5UTR, 2bFL & 2b5UTR) expressed lower levels of OKL38 
protein as compared to those without the 5UTRs (i.e. 1a/2aORF, 1a/2a3UTR, 2b3UTR 
& 2bORF). The 5UTRs derived from HuOKL38-2a and -2b variants seem to exert 
strong translation suppression activities, while that from HuOKL38-1a appeared slightly 
weaker. Comparing 1aFL, 1a5UTR and 1a/2a3UTR suggest that the 3UTR of OKL38 
seems to possess some translation enhancing activities (Fig. 4.37A-C). 
To ensure that the translation suppression of the OKL38 5UTRs observed in 
figure 4.37C was not due to different levels of transcription, half of the transfected Chang 
Liver cells were used for RNA extraction and the total OKL38 transcripts were 
determined using one step RT-PCR (Fig. 4.37D). Similar level of OKL38 transcripts 
were detected in all the Chang Liver cells transfected with constructs carrying OKL38 
cDNA and no transcripts were detected in cells transfected with control vector (Fig. 
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4.37D). Equal levels of OKL38 transcripts were found in the transfected cells and the 
difference observed in the OKL38 protein level was due to the presence of the 5UTRs. 
The desire minimum PCR cycles of 22 were determined for detection of OKL38 
transcripts in the transfected Chang Liver cells without undesirable amplification of the 
possibly contaminated DNA constructs (Fig. 4.37F). 
To further characterize the regions that are involved in translational suppression 
of OKL38 protein, several deleted 5UTRs of the HuOKL38-1a and 2a variants were 
generated by PCR as illustrated in figure 4.38. These deleted constructs uses either the 
OKL38 or the SEAP protein as the reporter gene to determine the level of translation. 
The various 5UTRs deleted constructs (pcDNA-3.0) carrying the OKL38 as the reporter 
gene were transfected into Chang liver cells and Western blot analysis was performed on 
the protein extracted from these transfected cells (Fig. 4.39A). In addition, these deleted 
OKL38 5UTRs, including two additional fragments (2aD4 and E4) (Fig. 4.38), were 
subsequently cloned into the pSEAP2-CV and transfected into both Chang liver and 
PLC/PRF5 liver cancer cell to confirm the translation suppressive effect of the OKL38 
5UTRs observed ealier (Fig. 4.39A). 
The deletion of the first 45 bp from the HuOKL38-1a 5UTR (1aD1) allowed 
recovery of the translational efficiency to more than 60 % and 40 % in the OKL38 (Fig. 
4.39A) and SEAP (Fig. 4.39B) reporter system, respectively, providing evidence that the 
regions between 156nt to 111nt of the 5UTR is crucial for translational suppression. 
Interestingly, a small uORF of 10 amino acids with internal translation initiation codon in 
this region was identified (Fig. 4.40A). Subsequent deletion of the UTR increased the 
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translational efficiency of the OKL38 protein indicating that other factors such as 
structured 5UTR might be involved in translational regulation.   
The deletion of the HuOKL38-2a 5UTR up to 34nt (E4) led to a surge in 
translational efficiency, which was comparable to the positive control (Fig. 4.39A & B). 
This demonstrated that almost the whole of HuOKL38-2a 5UTR, from 421nt to 34nt, 
effectively suppressed the translation of OKL38 protein in both reporter systems. This 
region coincidentally corresponded to exon 1 of the OKL38 gene. There is no significant 
difference in the levels of translation between 2aD2 (-219nt) and 2aD3 (-128nt), whereas 
the construct 2aD4 (-80nt) showed a significant increase in translational efficiency in 
both the Chang Liver and PLC/PRF5 cells (Fig. 4.39B). This relief of translational 
suppression may be attributed to a small uORF detected within the region from 128nt to 
80nt (Fig. 4.40B). This uORF have an internal translation initiation site (AUG) between 
80nt (2aD4) and 34nt (E4) (Fig. 4.40B), which led to a sudden increase in translational 
efficiency upon deletion (Fig. 4.39B). This deletion is instrumental to the observed 
increase in translational efficiency. Collectively, the differential levels of translational 
efficiency as shown provided evidence that the second AUG in the uORF might play a 
very important role in translational suppression. 
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CHAPTER 5: DISCUSSION 
5.1 The Human OKL38 gene 
5.1.1 Features in OKL38 gene 
The importance of OKL38 gene in cancer had previously been demonstrated 
(Huynh et al., 2001) and further reinforced in this study. The human OKL38 gene was 
cloned, sequenced and characterized to decipher the function(s) and regulation(s) of this 
potential tumour suppressor. The human OKL38 gene reported in this study was cloned 
and sequenced in advance of the published human genome sequence (Lander et al., 2001; 
Venter et al., 2001). The sequence data from this study showed two regions of mismatch 
and was verified to contain a 550 bp longer CCCT repeats as compared to the published 
human sequence. The 300 bp unsequenced region in these repeats can be confidently 
assumed to contain CCCT repeats as the same signals (CCCT) in the sequencing 
electropherogram diminishes toward the center of this region (data not shown). The 
functional importance of the CCCT repeats in the human OKL38 is unknown at the 
present time. However, the instability of CCCT repeats was highlighted in several 
reports suggesting that the different repeats length was due to genomic instability 
(Kosteas et al., 1997; Fiskerstrand et al., 1999). Fiskerstand et al. (1999) have shown that 
specific regions in intron 2 of the rat preprotachykinin-A gene contains a 128 bp of 
CCCT tandem repeats domain. This domain could support reporter gene expression in 
mouse embryonic stem (ES) cells that have been induced to differentiate but not in the 
undifferentiated ES cells. This would suggest that this region functions as a highly 
  DISCUSSION 
________________________________________________________________________ 
 134
restrictive enhancer and may be associated with differentiation. Similarly, the CCCT 
repeats located in intron 2 of the OKL38 gene may associate with differentiation as 
postulated in the previous report (Huynh et al., 2001). The CCCT repeats is located 1.2 
kb upstream of the promoter P1 initiation site and it is likely that this region functions as 
a restrictive enhancer for P1 promoter (Fig. 4.2).   
An approximately 500 bp of dinucleotide CA repeats is localized to intron 1 of 
OKL38 gene (Fig. 4.2). CA repeats are widespread throughout the human genome, 
representing ~0.25% of the human genome. They are the most common dinucleotide 
polymorphism among the microsatellite DNA fraction (Lander et al., 2001). Human 
genes with polymorphic intronic CA repeats includes the human interferon- gene 
(Awad et al., 1999), the epidermal growth factor receptor gene (Han and Nakamura, 
1998) and the cystic fibrosis cellular stress response (CFTR) gene (Mateu et al., 1999) 
among others. An approximately 20 bp random deletion in the CA repeats region was 
found in the sequenced OKL38 gene suggesting polymorphism in this region. Recent 
report by Hui et al. (2003) have highlighted a discovery that dinucleotide CA repeats of 
variable length found in the intron 13 of human eNOS gene promotes intron removal. 
They have shown that the ribonucleoprotein (hnRNP) L, a member of the hnRNP family, 
is the major factor that binds specifically and in a length-dependent manner to the CA-
repeat enhancer. Although the polymorphic nature of this region in the human OKL38 
gene has not been established, the intronic CA repeats in the intron 1 of human OKL38 
gene may serve as docking sites for hnRNP L factor to bind and regulate the differential 
splicing of this gene. Evidence to this can be drawn from the alternative splicing 
occurring at the 5 end of OKL38 gene, where the CA repeats are present. 
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The genomic organization of human OKL38 gene and its splicing pattern have 
been established in this study. The splicing pattern bears similarity to that of the human 
and mouse thioredoxin reductase 1 (TXNRD1) gene (Osborne and Tonissen, 2001). 
Differential promoter usage and alternative splicing at the 5-region of the TXNRD1 are 
highly similar to that of the OKL38 gene, except that the gene contains 16 exons as 
compared to OKL38 gene, which consists of 8 exons. The similarity in splicing pattern of 
TXNRD1 and OKL38 gene, coupled to the presence of a Pyr_redox domain in both 
genes suggests that OKL38 may be a new member of this family. 
5.1.2 Promoters of human OKL38 gene 
Several putative transcription factors binding sites have been identified within the 
300 bp upstream region of the P1 transcription start site. A CpG island of 215 bp, located 
746 bp precedes this TATA-less promoter upstream of promoter P1 initiation site. CpG 
islands are frequently associated with 5-regulatory sequences of housekeeping genes and 
genes with a more tissue-restricted pattern of expression (Gardiner-Garden and Frommer, 
1987). This characteristic was reflected in the expression profile of OKL38 in both the 
human and rat, where the transcripts are ubiquitously expressed in all tissues with 
significantly high expression in liver, kidney, ovary and testis (Fig. 4.6-8, 4.17 & 4.19). 
Putative Initiator (Inr) with the consensus Py-Py-A+1-N-T/A-Py-Py where A+1 is the 
transcriptional start site (Burke and Kadonaga, 1997) was identified in promoter P1 
suggesting that this core sequence is likely responsible for driving transcription (Fig. 4.3). 
Additional support for this conclusion is the presence of a putative downstream promoter 
element (DPE) in promoter P1 that is also found in about 20% of the TATA-less 
promoter containing Inr (Burke and Kadonaga, 1997). 
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Transcription factors binding sites identified within promoter P1 appears to differ 
from those observed in the promoter P2, suggesting that they may be differentially 
regulated. Interestingly, no typical promoter elements such as TATA or CAAT box, Inr 
or DPE were identified in the putative promoter P2 suggesting that other novel elements 
might regulate this promoter. This observation might help to explain the seemingly low 
levels of promoter P2 activities, where low levels of transcripts (i.e. HuOKL38-2a, -2b & 
-2c) were produced from this promoter. Further characterization of these promoters is 
needed to establish their regulatory functions. 
Three full-length OKL38 variants were cloned in this study. The HuOKL38-1a 
and HuOKL38-2a mRNA isoforms are expressed from different promoters; thus, possess 
different 5UTR (Fig. 4.9). These two mRNA isoforms encode for the same ORF (477 
amino acids) verified by TNT analysis (Fig. 4.10). The lethal effect of this OKL38 
protein isoform suggests that this protein has to be regulated in a precise and controlled 
manner. The observation bears similarity to that of the p53 protein, as abnormal 
regulation of this gene causes the cells to become cancerous or lethal to its own survival 
(Smith et al., 2003). Therefore, the use of 2 different promoters to produce 2 mRNA 
isoforms coding for the same protein is far from redundant. The intrinsic regulation of 
OKL38 protein at the translational level with possible cis-regulatory elements in the 5 
UTR was demonstrated in this study. 
5.1.3 The origin of human OKL38 isoforms 
Sequence analysis of the cloned OKL38 variants showed that the 1st AUG on the 
HuOKL38-2b and -2c transcripts conform to the Kozaks consensus sequence (Kozak, 
1981; Kozak, 1984; Kozak, 1986), except HuOKL38-1a and -2a. Interestingly, all the 
  DISCUSSION 
________________________________________________________________________ 
 137
internal in-frame AUGs identified in HuOKL38-1a, which were also present in all the 
other human OKL38 variants, does not conform to the Kozaks sequence (Fig. 4.11). The 
efficacy of translating OKL38 appeared to be independent of Kozaks sequence (Fig. 
4.37A-C). The 5UTRs in this instance played a more significant role in controlling the 
efficiency of translation of OKL38 protein.  
Several OKL38 isoforms (61 kDa, 52 kDa and a doublet 38 kDa) were detected 
by Western blot analysis (Fig. 4.10 & 4.31). The 61 kDa OKL38 isoform might have 
been translated from HuOKL38-2b or -2c transcripts, while the 52 kDa protein is most 
probably derived from HuOKL38-1a or 2a transcripts. However, we do not exclude the 
possibility of internal translational initiation at in-frame AUG in the mRNAs of 
HuOKL38-2b and -2c variants. Small non-inframe ORFs were detected within the first 
AUG and the internal AUG (i.e. between AUG-a and AUG-1) in both the HuOKL38-2b 
and -2c transcripts (Fig. 5.1), which may recruit the translation machinery and reinitiate 
translation as described for the C/EBP family of transcripts, Fli-1 and CNP2 (Section 
1.2.2, Literature Review). Similarly, the 38 kDa doublet might have derived from usage 
of internal translation start site with the same mechanism as small non-inframe ORFs 
were also observed within the 52kDa ORF (Fig. 4.11). Although no cleavage sites for 
caspase1 to 10, enterokinase, granzymeB and thrombin were found within the full-length 
OKL38 protein using ExPASy peptide cutter (Gasteiger E et al., 2005), post-translational 
processing of full-length protein by other endogenous peptidases could also be 
responsible for OKL38 protein isoforms observed in the present study.  
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5.1.4 OKL38, a putative bi-functional protein 
Proteins are modular in nature and are generally comprising of several domains of 
rather diverse functions. The various isoforms of OKL38 may contain only certain 
domains but serve different functions in the cells. The cloned HuOKL38-1a encoded a 
longer protein of 52 kDa as compared to the previously cloned OKL38 cDNA (Huynh et 
al., 2001). The presence of a TrkA and Pyr_redox domain in OKL38 protein suggests that 
the gene may belong to the larger family of pyridine nucleotide-disulphide 
oxidoreductases and may share similar functions from this family of proteins. These 
proteins include Trx reductase and GSH reductase, and most probably also include AIF, 
AMID/PRG3 and AIFL (Fig. 4.23). 
In addition to the Pyr_redox domain, the Trx reductase and GSH reductase 
contained a dimerization domain, which functions in protein-protein interaction. 
Similarly, AIFL contained a Rieske domain in addition to its Pyr_redox domain (Fig. 
4.23). The cell death associated function of OKL38 demonstrated in this study was 
similar to those observed in over-expression of AIF, AMID/PRG3 and AIFL in cell lines. 
The oxidoreductase function in the AIF, AMID/PRG3 and AIFL is not required for its 
apoptogenic function (Miramar et al., 2001; Loeffler et al., 2001; Wu et al., 2002; Ohiro 
et al., 2002; Xie et al., 2005). The N-terminal portion of AIF and the Rieske domain in 
AIFL were sufficient to induce apoptosis (Loeffler et al., 2001; Miramar et al., 2001; Xie 
et al., 2005) suggesting that the Pyr_redox domain in OKL38 may be redundant for its 
cell death function. This indicates that the TrkA domain in the OKL38 may be sufficient 
to induce cell death.  
  DISCUSSION 
________________________________________________________________________ 
 140
The oxidoreductase function of Pyr_redox domain in the AIF protein and its role 
as free radical scavenger had previously been demonstrated (Klein et al., 2002). The 
Pyr_redox in OKL38 may play an important role in protecting the cells against oxidative 
stress via mopping up free radicals generated through respiratory processes. This 
postulation was further supported by the results from microarray analysis which showed 
the OKL38 was one of the genes that was induced in MCF7 cells by hydrogen peroxide, 
mendonine and t-butyl-hydrogen peroxide treatment (Chuang et al., 2002). On the other 
hand, up-regulation OKL38 by these oxidative stress-inducing agents might contribute to 
the cell death signalling pathways. The roles of OKL38 during oxidative stress are still 
unclear at the present moment. These observations seem to suggest that genes containing 
the oxidoreductase domain may be bifunctional, regulating cellular redox and cell death. 
5.1.5 OKL38 - An ancient protein with diversified functions 
Evolution has a mysterious way of shaping proteins and their functions. The 
conserved domain search program (NCBI) detected a TrkA domain in the full-length 
OKL38 protein and this domain belongs to a flavoprotein involved in bacterial K+ 
transport. The TrkA gene has been described in several prokaryotes such as Escherichia 
coli and Vibrio vulnificus (Hamann et al., 1987; Chen et al., 2004). The mammalian 
counterpart was suggested to be the  subunits of voltage-gated potassium channel (Jan 
and Jan, 1997). In the E. coli, the TrkA protein contains two internal repeats each with an 
NAD(H)-binding motif, and the purified TrkA protein binds NAD(H) (Schlosser et al., 
1993) (Fig. 4.23). The eukaryotic voltage-gated potassium channel may contain four  
subunits, each with sequence similarity to the NAD(P)H-binding domain of 
oxidoreductase, similar to TrkA (Jan and Jan, 1997). Pyr_redox domain consists of a 
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small NADH-binding domain within a larger FAD-binding domain. These observations 
suggest that both the TrkA and Pyr_redox domains identified in the OKL38 protein might 
bind onto substrate such as NAD(P)H, NADH or FAD. Comparing the TrkA domain 
from E. coli and the OKL38 protein, the TrkA and Pyr_redox domain in OKL38 seem to 
be evolved from the two TrkA domain repeats observed in E.coli. One of TrkA domain 
from the TrkA protein in E. coli appears to be conserved in OKL38, while the second 
TrkA domain seems to have evolved into a Pyr_redox domain (Fig. 4.23). The over-
expression of TrkA resulted in protein aggregates (Hamann et al., 1987), further 
illustrating the similarity observed between TrkA and OKL38 protein. However, there is 
no evidence available showing that OKL38 is a component of the mammalian potassium 
transport system. These observations point toward the possibility that OKL38 might have 
evolved from an ancient protein that had undergone gene duplication and evolved 
separately from their potassium channel  subunits cousins, to be functionally diverse.       
5.2 Rat is a suitable model to study OKL38 gene 
5.2.1 OKL38 is highly conserved in human, rat and mouse 
Multiple sequence alignment (EMBL) delineates the regions of similarity for 
OKL38 protein from rat, mouse and human (Fig. 4.21). The OKL38 protein was highly 
conserved in all the three species suggesting the importance of this protein in cellular 
functions such as growth and differentiation. The Pyr_redox domain identified in human 
OKL38 was common to all three species. This domain is also present in the well-
characterized GSH reductase and Trx reductase (Fig. 4.23). BLAST search using the 
deduced amino acid sequence against the non-redundant database identified several 
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proteins of unknown functions such as human C8ORF1 (GenBank Accession No. 
NP_004328) and the bacteria conserved protein, BH1623 (GenBank Accession No. 
NP_242489) from Bacillus halodurans (Fig. 4.23). The C8ORF1 is a predicted protein 
from the human chromosome 8, with an identity of 49% and a similarity of 62% to rat 
OKL38 protein. An unknown conserved protein, BH1623 from B. halodurans, shows a 
lower homology to that of the rat OKL38 with an identity of 39% and a similarity of 
44%. Results from sequence comparison studies seem to advocate that the C8ORF1, 
BH1623, AIF, AMID/PRG3, AIFL, Trx reductase, GSH reductase and OKL38 may 
belong to the larger family of pyridine nucleotide-disulphide oxidoreductases. 
5.2.2 Genomic organization of rat OKL38 gene 
The genomic organizations of the human and the rat OKL38 gene have been 
deciphered in this study. The genomic structure of both the human and rat OKL38 gene 
bears similarity with each containing 8 exons with exon 5, 6 and 7 possessing identical 
sizes (Fig. 4.1B & 4.15). These three exons encoded almost the whole of the putative 
TrkA domain. The putative pyridine nucleotide-disulphide oxidoreductase domain 
resides in exon 8, the last exon in both species. The predicted OKL38 spliced junction in 
both species contained the GT/AG dinucleotides consensus sequences. Differential 
promoter usage and alternative splicing were utilized by both the human and rat to 
regulate OKL38 transcription. Recent evolution events may have fine-tuned the 
regulation of OKL38 in each individual species as the splicing pattern appear different, 
but preserving the protein and gene structure.  
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5.2.3 The presence of small upstream ORF (uORF) 
Three OKL38 cDNA variants from each of the human and rat were identified and 
cloned in this study. The NCBI annotation project predicted the human OKL38 to be 
about the same length as the RtOKL38-2.0. Two mouse OKL38 cDNAs of 1982 bp 
(GenBank Accession No. BC022135) and 2383 bp  (GenBank Accession No. BC006032) 
have also been reported. Sequence analysis of these cloned rat OKL38 cDNAs with those 
from the human and mouse showed that the transcripts contained different 5UTRs. 
Small uORF detected in the 5UTR of the RtOKL38-2.0, -2.3 and -2.3A variants may be 
involved in post-transcriptional regulation of protein synthesis, as they are often used to 
down-modulate the production of potent proteins such as cytokines, growth factors, 
protein kinases and transcription factors (Kozak, 2002). The cytotoxicity of OKL38 when 
over-expressed and the existence of different mRNA isoforms that encoded for the same 
protein suggest that translational regulatory cis-elements may exist in the 5UTR of the 
mRNA to fine-tune the regulation of OKL38 protein. The presence of uORFs in the 
5UTRs of human and rat OKL38 variants suggests that they may have similar 
translational regulatory control mechanism (Fig. 4.12A).  
5.2.4 Rat OKL38 isoforms and tissue distribution 
Four human OKL38 variants were identified of which three were cloned, while 
only three variants were cloned from the rat. None of the OKL38 variants identified so 
far contain all the eight exons with the exception to RtOKL38-2.3, which was identified 
in this report. The RtOKL38-2.0 and HuOKL38-1a transcript consists of exon 3-8 with 
both having an approximate size of 2 kb. The RtOKL38-2.0 and HuOKL38-1a transcripts 
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encodes for proteins of 478 and 477 amino acids, respectively. Both proteins differ only 
in one amino acid and possess a high homology of 85% (Fig. 4.21).   
The expression profiles of all the OKL38 variants were quite different in the 
human and rat except for HuOKL38-1a and RtOKL38-2.0, which showed similar tissues 
distributions in both species. Generally, both RtOKL38-2.0 and HuOKL38-1a are highly 
expressed in the liver, kidney and ovary of the respective species (Fig. 4.6-8 & 4.17-19). 
These transcripts were derived for promoter P1 of the human and rat OKL38 gene (Fig. 
4.8 & 4.19) indicating that the promoter P1 of both species was regulated in similar 
manner. The discrepancy in OKL38 expression in the ovary of the human and rat is most 
probably attributed to the non-homogenous human ovarian tissue used in the RT-PCR 
and MTN, which was further supported by the in situ hybridization results showing that 
OKL38 transcripts were observed to be highly expressed in the granulosa cells of the rat 
ovaries. However, one does not rule out the possibilities where the levels of OKL38 
differ in both human and rat ovaries.  
Beside the HuOKL38-1a and RtOKL38-2.0 variants, differences were prominent 
in the other OKL38 variants from both species. The HuOKL38-2b and -2c variants 
encodes for proteins of 61 and 59 kDa, respectively, while only a single 52 kDa protein is 
encoded by the rat OKL38 variants. Interestingly, sequence comparison studies 
performed between the human and rat OKL38 variants showed that only the coding 
region for the 52 kDa protein was conserved and contained two putative domains, the 
Pyr_redox and the TrkA (Fig. 4.21). Over-expression of either rat or human OKL38-
eGFP recombinant protein in cell lines localized the protein to the cytoplasm and 
subsequently leading to cell death (Fig. 4.13, 4.14 & 4.24) suggesting a conserved 
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function. No alignment was observed in the 5 UTR of the other OKL38 variants (i.e. 
HuOKL38-2a, -2b & -2c; RtOKL38-2.3 & -2.3A) in the two species indicating that 
regulation of these variants could be species specific. 
Several larger transcripts ranging from 4.0 to 9.0 kb were detected in the rat liver 
and kidney, and human liver tissues by Northern Blot analysis (Fig. 4.7 & 4.17). In the 
present study, these larger transcripts were not characterized. 5RACE analysis did not 
amplify any larger transcripts other than the 1.1 and 1.4 kb fragments from the rat kidney 
cDNA library. However, one does not exclude the possibility that they were derived as a 
result of differential splicing at the 3 end of the gene or other rare OKL38 variants 
expressed at extremely low levels.  
The similarities in the genomic structures, cDNAs and proteins between the 
human and rat OKL38 gene indicate that the results observed in rat can be extrapolated to 
human counterparts. In general, the rat may serve as a suitable model to address most of 
the questions concerning the functions and regulations of OKL38.  
5.3 Breast Cancer and regulation of OKL38 by human chorionic 
gonadotropin (hCG) 
5.3.1 Pregnancy and hCG induced expression of OKL38 in rat 
mammary gland  
Regulation of OKL38 during pregnancy in rat mammary glands has previously 
been demonstrated (Huynh et al., 2001). In this study, results from RT-PCR and Northern 
blot analysis showed that only the RtOKL38-2.0 variant was induced by hCG in the 
mammary and ovary. Low levels of OKL38 expression were detected in the mammary 
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epithelial cells of non-pregnant rat where the mammary gland is highly undifferentiated 
(Fig. 4.25 & 4.28A). The expression of OKL38 protein in mammary gland was observed 
to be high during pregnancy where the epithelial cells undergoes differentiation and 
throughout lactation, a stage where the breast acquired fully differentiated condition 
(Russo et al., 2005). After weaning, all the secretory units of the breast regressed and the 
mammary epithelial cells undergo apoptosis and remodulation (Russo et al., 1992). At 
this stage, the OKL38 expression returned to basal level as observed in figure 4.25. The 
close relationship between the degree of mammary epithelial differentiation and OKL38 
expression advocate the involvement of this protein in maintaining mammary epithelial 
cell differentiation. This postulation was further supported by the fact that OKL38 is 
highly expressed in the liver and kidney, which is characterized by relatively low cellular 
turnover and extensive differentiation. 
Previous in vitro and in vivo studies demonstrated the growth inhibitory properties 
of OKL38 (Huynh et al., 2001) and coupled to the lost of transcript observed in several 
breast cancer cell lines lists its importance in the process of mammary tumourigenesis. 
Pregnancy and hCG treatment have been shown to protect the breast from carcinogenesis 
(Russo et al., 1990b; Russo et al., 1990a; Russo et al., 1991). Here, hCG and pregnancy 
were demonstrated to induce OKL38 expression in mammary epithelial cells from which 
breast cancer derive. Taking these observations together, it is tempting to speculate that 
OKL38 may be one of the downstream effector proteins involved in pregnancy and hCG 
induced protection of the breast against carcinogenesis.   
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5.3.2 OKL38 is up-regulated by hCG in the rat ovary 
The ability of hCG to induce OKL38 expression in the granulosa cells and the 
corpus lutes have been demonstrated. CG levels rise during the advancement of 
pregnancy and recombinant hCG has been shown to induce enlargement of the rat ovary 
due to the formation of the corpora lutea (Russo I. H., personal communication). In the 
ovary, hCG binds to the granulosa cells of the ovary through LH-CG-R, a seven 
transmembrane G-protein-coupled-receptor; this induces ovulation and maintains the 
corpus luteum that is essential for maintenance of pregnancy until the placenta becomes 
fully functional (Leung and Steele, 1992; Stouffer, 2003). The above observations 
suggested that the induction of OKL38 expression by hCG could be mediated through the 
LH-CG-R signalling pathway. Since CG is required for maintenance of progesterone 
hormone production during pregnancy (Devoto et al., 2002), it is also possible that hCG-
induced OKL38 expression is mediated through progesterone production. Although no 
cAMP responsive element or progesterone responsive element were detected within the 1 
kb region of putative promoter P1 (RtOKL38-2.0), other cis-elements such as AP1, AP4, 
NFKappaB, and CEBP were detected using the program MatInspector V2.2. These 
putative transcription factors binding sites may contribute to the induction of OKL38 by 
hCG. 
Ovarian cancers derived from the granulosa cell are rare with an incident 
frequency of approximately 1-2 % and the recurrence of this cancer after resection is very 
high (Amsterdam and Selvaraj, 1997). Transgenic mice hypersecreting LH led to 
elevated serum levels of estrogens, androgens, progesterone, corticosteroids and prolactin 
(Renehan et al., 2004; Keri et al., 2000; Kero et al., 2000; Mann et al., 1999), and lead to 
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eventual formation of granulosa cell tumours (Risma et al., 1995; Owens et al., 2001). 
Surprisingly, these transgenic mice treated with ovulatory doses of hCG prevented the 
formation of granulosa tumours and instead induce the formation of a differentiated 
luteoma (Owens et al., 2002). Since OKL38 is inducible by hCG in the granulosa cell and 
is postulated to function in maintaining cellular differentiation, it is possible that hCG 
induced the formation of differentiated luteoma in the LH transgenic mice via up 
regulation of OKL38. The above postulation may be over simplified as other hormones 
and genes were also involved in orchestrating the effects of pathways switching (Owens 
et al., 2002), from granulosa cell tumour to differentiated luteoma formation. 
Investigating the effects of hCG on expression of OKL38 in these LH transgenic mice 
will shed some light on the functions of OKL38 in granulosa cell tumours.  
5.4 Kidney Tumour and Hepatocellular Carcinoma (HCC) 
5.4.1 Novel biomarkers for kidney tumour and HCC 
Failure to detect cancers at an early stage is the main reason for unsuccessful 
treatment of operable diseases. The ability to predict outcomes of the disease will enable 
customized treatments and therapeutic intervention. Thus, identifying and development 
of useful prognostic and diagnostic biomarkers is an important field in cancer biology. 
OKL38 has been shown to be highly expressed in the liver and kidney. The OKL38 
mRNA transcripts were down-regulated in several breast cancer cell lines and DMBA-
induced mammary tumour (Huynh et al., 2001). These preliminary studies and the 
growth inhibitory property of OKL38 advocate the potential of this gene as a biomarker 
for kidney and liver cancers.  
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All the kidney tumour samples used in this study (except CPA) were of the clear 
cell histological type, which is the most common form of RCC. The results from CPA, 
immunohistochemistry and Western blot analysis indicate that OKL38 was down-
regulated in the kidney tumour at both the mRNA and protein levels. Although the 
OKL38 transcripts were marginally down-regulated in some of the kidney tumour as 
compared to the adjacent benign tissue, the protein were lost in the tumours as shown by 
the immunohistochemical staining and Western blot analysis (Fig. 4.31 & 4.32). 
Interestingly, both the 38 and 61 kDa OKL38 isoforms were lost in the kidney tumour 
and the 61 kDa isoform seem to be a more effective biomarker for differentiating normal 
from tumour tissue than the 38 kDa isoform as shown in Figure 4.31A. 
Immunohistochemistry analysis failed to detect OKL38 protein in 64% (14/22) of the 
kidney tumour most probably attributed to the loss of the 38 and 61 kDa isoforms in the 
majority of the tumours. Due to the insufficiency of patient tissue samples, it is not 
possible at this time to provide any statistically significant conclusion. However, these 
preliminary results seem encouraging that the various isoforms of OKL38 proteins may 
serve as important biomarkers for detection of kidney cancer, especially of the clear cell 
histological type. Both larger patient sample size and diseases outcome information are 
necessary to further address this issue.     
In the liver, the 52 and 61 kDa OKL38 isoforms are expressed at low levels while 
the 38 kDa OKL38 isoform is readily detected using the same antibody, suggesting that 
the various isoforms maybe tissue specific. Due to the complexity of the disease, the 
present TNM system and grading by cellular differentiation cannot accurately predict the 
disease outcome of all HCC patients. Loss or absence of OKL38 was observed in 64.2 % 
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of the HCC examined as compared to its ABL tissue. The loss of OKL38 protein in HCC 
was correlated with the stages of the disease (p=0.0042), indicating the potential use of 
OKL38 expression as a biomarker to improve the present system of tumour staging. 
OKL38 may be used concurrently with other HCC markers such as DNA ploidy, cellular 
proliferation markers, nuclear morphology, cell cycle regulators, oncogenes and their 
receptors, tumour suppressor, apoptosis related factors, telomerase activity, adhesion 
molecules, proteinases, angiogenesis regulators and tumour associated antigen (Qin and 
Tang, 2004), to refine the TNM staging system for HCC. The fine tuned system may 
include more sub-groups increasing the accuracy of prognosis. However, no significant 
correlation was established between OKL38 expression and the survival of patients. 
OKL38 is localized intracellularly and significant loss of the protein is only detectable in 
HCC of higher tumour stage indicating that it may not be a useful diagnostic biomarker 
for earlier detection of HCC. Since the 38 kDa OKL38 isoform is differentially lost in the 
liver tumour, it is important to determine the origin of this isoform.   
5.4.2 Mechanisms of OKL38 down regulation in cancer 
Over-expression of the OKL38 protein in A498, Chang liver and BRL cells led to 
cell rounding and subsequently cell death. This effect could be attributed to cell cycle 
arrest and apoptosis (Wang et al., 2004). These observations led to the speculation that 
OKL38 may play an important role in regulating cell death in tumour and loss of the 
protein may lead to the development and/or progression of the cancer as a result of 
altered equilibrium between cell death and survival. Thus, revealing the regulation of 
OKL38 in cancers is of immense importance. As observed in these series of studies, both 
transcriptions and translations were involved in the down-regulation of OKL38 in 
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cancers. These observations include (1) low levels of OKL38 transcripts were detected in 
breast cancer cell lines (Huynh et al., 2001); (2) lower levels of OKL38 transcripts were 
detected in the kidney tumours compared to adjacent benign tissue (Fig. 4.30); (3) 
OKL38 transcripts were lost or down-regulated in 37% of the HCC investigated (Fig. 
4.33); (4) 42 % (8 of 19) of the paired ABL/HCC, 4 liver (Fig. 4.33) and 1 kidney cancer 
cell lines OKL38 transcripts levels did not correlate with the protein expression.  
5.4.2.1 Hypermethylation and Loss of Heterozygosity potentially down 
regulate OKL38 expression in HCC 
Many possible mechanisms could be involved in the down-regulation or lost of 
OKL38 protein in tumours. Hypermethylation at the CpG islands in the promoter region 
has been known to silence tumour suppressor genes (Toyooka et al., 2001). A CpG island 
has been identified in each of the OKL38 promoters, which may be involved in silencing 
of the OKL38 gene in cancers. The OKL38 gene is localized to chromosome 16q23.3, 
which is susceptible to LOH in a variety of tumours (Larsen et al., 2000). This region has 
been described as the second most active fragile site (FRA16D) in the human genome 
(Bednarek et al., 2001; Bednarek et al., 2000; Glover et al., 1984; Ludes-Meyers et al., 
2003) and LOH of two potential tumour suppressor genes (E-cadherin and WWOX) 
resided in this region of HCC have been described (Niketeghad et al., 2001; Slagle et al., 
1993; Park et al., 2004). It is possible from here that this mechanism may play a role in 
down-regulating the OKL38 transcripts in some of the HCC investigated. On the 
contrary, Riou et al. (2002) have recently investigated the expression of gene residing on 
chromosome 16q23.3-24.1 in HCC and have identified that OKL38 was over-expressed 
in HCC. In this study, only 3 of the 19 paired ABL/HCC samples showed significantly 
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higher levels of OKL38 mRNA in HCC tissues, while approximately 50% of these cases 
showed no significant differences in the transcript levels. These observations may 
indicate that loss of OKL38 protein occurred only in a subset of HCC. 
5.4.2.2 Down-regulation of OKL38 translation by small upstream open 
reading frame and long structured 5UTRs in cancers 
Aberrant expression of growth-related genes by translational mechanisms makes a 
significant contribution to cell transformation. These mechanisms of translational control 
of growth factors and proto-oncogene expression have been extensively reviewed (Willis, 
1999; Clemens, 2004; Dua et al., 2001; Pickering and Willis, 2005). The discrepancy 
between the OKL38 transcripts and protein levels was observed in HCC, which prompt 
the investigation into the molecular mechanisms responsible for the absence of OKL38 
protein in HCC. The intact ORF of the OKL38 transcripts (exon3-8) was observed in 5 
patients and 4 liver cancer cell lines suggesting that the loss of OKL38 protein in HCC 
was not due to mutation or deletion (Fig. 4.35). The 5UTRs of all the three OKL38 
variants (HuOKL38-1a, -2a & -2b) derived through differential promoter usage and 
alternative splicing have been demonstrated to suppress the translation of OKL38 protein 
in both TNT system and transfected cells (Fig. 4.37). These observations suggested that 
besides transcriptional regulation of OKL38 transcripts, post-transcriptional regulation 
also played an important role in regulating OKL38 protein expression.  
Two thirds of the mRNAs that encodes for proto-oncogenes or factors related to 
cell proliferation contains atypical 5 untranslated regions which are more than 200 bases 
long and/or have more than one AUG codon (Kozak, 1987; Kozak, 1991). It was reported 
that upstream open reading frames (uORF) found in 5UTRs of the bcl2 gene play a role 
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in translational suppression (Harigai et al., 1996). An uORF of 10 amino acids was 
detected in HuOKL38-1a transcripts, while two uORF of 21 and 30 amino acids were 
identified in the 5UTRs of the HuOKL38-2a transcripts. Similarly, the 21 amino acids 
uORF was also present in the HuOKL38-2b transcripts. The disruption of some of these 
small uORFs has lead to increase translational efficiency of the OKL38 protein (Fig. 
4.40), which supported the potential role of these uORFs in translational suppression in 
OKL38 mRNAs.  
The presence of these small uORFs may be insufficient to explain the differential 
lost of OKL38 expression in kidney and liver tumour and, cancer cell lines despite the 
presence of OKL38 transcripts with intact ORF. It is possible that other mechanisms may 
be responsible for the differential loss of OKL38 protein in HCC. Besides the uORFs, the 
long structured 5UTRs of the HuOKL38-2a and -2b transcripts may contain IRES, 
interacting with other ITAFs, to suppress the translation of OKL38 protein. Important 
genes such as MDM2, TGF and Bcl-2 expressed variants with long 5UTRs differing in 
length, exhibiting translational repression. The translation suppression effect by long 
structured 5UTRs and uORF have been reported (Willis, 1999) and reviewed in section 
1.2. RNA binding protein such as HuR has also been shown to bind to the IRES present 
in the 5UTR of p27, leading to down-regulation of the translation of p27 (Kullmann et 
al., 2002). ITAFs such as hnRNPK, La autoantigen, PTB protein and others may bind to 
the structured 5UTR to down-regulate translation of OKL38 mRNA. At this junction, it 
is possible that similar mechanisms involving RNA-binding protein/RNA complex, 
together with the 5UTRs might suppress the translation of OKL38 mRNA. These ITAFs 
may be over-expressed in cancer cell lines and tumours leading to differential 
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suppression of translation. Experiments are under way to identify possible RNA binding 
protein in the 5UTRs of OKL38 transcripts. 
The OKL38 antibody used in this study has been demonstrated to be specific for 
Western and immunohistochemical analysis (Fig. 4.31 & 4.32). Only the 38 kDa isoform 
of the OKL38 protein was readily detected in the ABL tissue, in contrast to the 52 kDa 
isoform cloned and characterized in this study. Beside internal initiation mechanisms as 
discussed in section 5.1.3, one does not rule out the possibility that the 38 kDa isoform 
might have been processed from the 52 and 62 kDa isoforms. The cancer cell lines used 
in this study may not have the necessary mechanism to process these exogenous larger 
isoforms as observed in the transfection study. In view of all these observations, the 
OKL38 gene may be differentially down-regulated in cancer at the transcriptional and 
translational levels, and probably also via post-translational modification of the pre-
OKL38 protein.  
5.5 OKL38  A stress related protein 
In recent years, the use of micro-array platform to study the transcriptome is 
becoming very common. Profiling the genes expression during certain treatments or 
developments may reveal the biological functions or pathways involved. OKL38 have 
been shown to be significantly induced or suppressed by chemicals such as hydrogen 
peroxide (HP), mendonine (MEN), t-butyl-hydrogen peroxide (TBH), phthalate esters 
and polycyclic aromatic hydrocarbon (PAH) (Chuang et al., 2002; Liu et al., 2005; 
Mahadevan et al., 2005). Physiological laminar shear stresses (LSS), which act as 
differentiative stimuli on endothelial cell, induced the expression of OKL38 transcripts 
(Wasserman et al., 2002). The differential expressions of OKL38 transcripts in these 
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treatments suggest that the gene may be involved in many physiological and cellular 
processes. 
Phthalate esters could induce male reproductive tract abnormalities in male rats 
exposed gestationally (Fisher, 2004; Fisher et al., 2003). OKL38 has been reported to be 
one of the genes that were down-regulated in the fetal testis of the rat following in utero 
exposure to a panel of developmentally toxic phthalates (Liu et al., 2005). Liu et al. 
(2005) have also identified the pathways disrupted by these compounds, which include 
cholesterol transport, steroidogenesis, intracellular lipid and cholesterol homeostasis, 
insulin signaling, transcriptional regulation, and oxidative stress. It is likely that OKL38 
may be regulated by one of these pathways and plays an important role in male 
reproductive tract development. The suppression of OKL38 transcripts by phthalate could 
be due to the down-regulation of LH-R (Liu et al., 2005), which is the common receptor 
for both LH and hCG. In this study, OKL38 was shown to be inducible by hCG in the rat 
mammary gland and ovary. In the testis, the CG may play a role in maintaining OKL38 
expression and phthalate-induced down-regulation of LH-R may consequently down-
regulate OKL38 expression. Coincidentally, all the genes involved in oxidative stress 
were also down-regulated in the phthalate exposed rat testis further supported the 
postulation that OKL38 is involved in oxidative stress. 
OKL38 is up-regulated by oxidative stress induced by chemical compounds such 
as HP, MEM and TBH (Chuang et al., 2002). Similarly, physiological LSS also induced 
the expression of OKL38 transcripts in cultured human umbilical vein endothelial cells 
(Wasserman et al., 2002). LSS induced many of the genes involved with antioxidant 
functions such as thioredoxin reductase and Cu/Zn superoxide dismutase, which play a 
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role in maintaining low levels of intracellular reactive oxygen species generated by LSS. 
The coordinated regulation of a diverse set of antioxidant effectors and the presence of a 
Pyr_redox domain in OKL38 protein strongly highlights the protective role of this protein 
in oxidative stress induced cellular damage.  
Other than oxidative stress, OKL38 is also induced by PAH (i.e. Benzo[a]pyrene) 
which is a common compound present in urban dust (Mahadevan et al., 2005). Exposure 
to PAHs can target the expression of regulatory proteins involved in activation, 
detoxification and DNA repair, thus altering the ability of the cells to maintain genomic 
integrity. OKL38 may function as a tumour suppressor to protect and prevent the 
transformation to cancer cell during exposure to PAHs. Evidences from these studies 
demonstrated that OKL38 is differentially regulated by cellular stress and it might serve 
an important role in re-establishing equilibrium of the cellular environment. 
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CHAPTER 6: CONCLUSIONS AND FUTURE STUDIES 
In conclusion, the human OKL38 gene has been cloned, sequenced and the 
genomic organization revealed. Several important regions that may play important roles 
in the regulation of OKL38 gene are identified. In addition, three of the novel human 
OKL38 cDNAs are cloned and partially characterized. Several lines of evidences indicate 
that OKL38 is a conserved essential protein and may belong to the Pyr_redox family of 
proteins. The rat model was established with the cloning of three rat OKL38 cDNAs, 
deciphering its genomic structure and tissues distribution. The effects of hCG on OKL38 
expression in the rat mammary tissue and ovary was demonstrated using this model. The 
positive correlation between hCG-induced OKL38 expression and hCG-protection 
against mammary carcinogenesis suggests that OKL38 may function as the downstream 
effector protein of hCG-mediated protection against mammary carcinogenesis by 
maintaining cellular differentiation.  
The present data showed that OKL38 protein is down-regulated in a high 
proportion of kidney and liver tumours indicating that the protein may play a crucial role 
in the progression of the disease. Loss of OKL38 protein in a high proportion of primary 
HCCs, which positively correlate with tumour grade indicate that OKL38 might be a 
useful marker for refining the TNM staging system. Results from this study points 
towards the vital role of OKL38 in the survival of cancer cells and its loss in HCC may 
permit the cancer cells to escape the normal cell death mechanisms leading to 
uncontrolled growth. In view of these observations, induction of OKL38 translation may 
serve as a therapeutic alternative or adjuvant in combating HCC and be worth further 
investigation. 
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 Although much was known about OKL38 in this study, the functions and 
regulations of this gene are far from being understood. Characterization of the putative 
promoters will enable us to understand the regulation of OKL38 at the transcription level, 
which may reflect its intrinsic functions, as several chemical agents were involved in the 
induction and repression of the transcripts. The rat OKL38 promoter P2 seems to be 
active only in kidney making it an interesting candidate for the study of kidney tissue 
specific promoter. Further characterization of this promoter may lead to the development 
of vectors useful for kidney specific targeted gene expression. 
In-depth studies of the 5UTRs and the non-inframe ORFs in the main ORF (52 
kDa) is crucial to decipher the loss of the 38 kDa isoforms in both the liver and kidney 
tumours. Isoform-specific antibodies can be raised against the various OKL38 isoforms 
and exploit expression studies in tumour, including the kidney, ovarian and breast cancer. 
Small uORFs and non-inframe ORFs are known to lead to internal translation initiation 
during cellular stress such as nutrient deficiency. Since OKL38 expression is closely 
related to cellular stress, similar translational machinery may be involved and 
characterization of the 5UTRs may reveal novel isoforms of OKL38 involved in cellular 
stress. Finally, the generation of an OKL38 knockout animal seems tempting, which will 
advance our understanding of the functions of this important gene. 
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